CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 1 of 67 1.0 TITLE PAGE 
Protocol Title:  A Multi -Center, Double -Blind, Randomized, Vehicle -Controlled, Parallel -
Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® 
(tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control 
in the Treatment of  Stable Plaque Psoriasis  
Investigational  Product : Tazarotene Cream 0.05%  
Population : 
Study Design : 
Sponsor : 
Protocol Number:  
 
Protocol Date:  
Protocol History:  Approximately 855 males and non- pregnant  females , 18 y ears of ag e and 
older, w ith clinical diagnosis of  stable plaque  psoriasis  
A multi-center, double-blind, randomize d, vehicle -controlled, p arallel -
group bioequivalence s tudy with clinical endpoints comparing  Tazarotene  
Cream 0.05% to TAZORAC® (tazarotene) Crea m 0.05% and both active 
treatmen ts to a vehicle c ontr ol in the treatment  of stable pl aque p soriasis 
Fougera Pharmaceuticals Inc. 
0453-01-01 / [STUDY_ID_REMOVED]
 
07/26/
2016 F INAL 
12/20/2016 Rev. 1 FINAL 
12/22/2016 Rev. 2 FINAL 
7/26/ 2016 (Original Protocol) 
12/20/2016 (Rev . 1) 
12/22/2016 (Rev . 2) 
This document is a privileged and confidential communication of Fougera Pharmaceuticals Inc. and 
. Receipt of this document constitutes an agreement by the 
recipient that no unpublished information contained herein will be disclosed without  and 
Fougera ’s written approval. This protocol should be stored in a limited access area. 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 2 of 67 
 
 2.0 KEY STUDY PERSONNEL AND FACILITIES  
Sponsor:  
 Fougera Pharmaceuticals Inc.  
60 Baylis Road 
Melville, New York, 11747  
 
CRO:  
  
 
 
 
Sponsor’s Representative:  
  
 
 
Tel:  
Fa
x:  
Email:  
 
 
 
Tel:  
F
ax:  
Email :  
 
CRO Representative:  
  
 
 
Tel:  
Fa
x:  
Email:  
 
Medical Monitor:  
  
 
Tel:  
Fa
x:  
Email:  
 
Biostatistician:  
  
 
Tel:  
Fa
x:  
Email:  
  
 
  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 3 of 67 
 
 3.0 SIGNATURE PAGE  
 
We, the undersigned, have carefully read this protocol and agree that it contains all the necessary information required to conduct the study. The study will be performed according to this protocol, all applicable Food and Drug Administration (FDA) regulat ions, International Conference on 
Harmonis ation  (ICH) guidelines and Good Clinical Practice (GCP)  standards.  
  
    
             Date     
 
 
   
    
           Date  
 
 
   
    
           Date  
 
 
   
    
              Date  
 
 
 
 
__________________________________________  _________________________ 
             Date  
 
 
   
  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 4 of 67 
 
 PRINCIPAL INVESTIGATOR’S SIGNATURE  
 
 I agree to conduct protocol 0453-01- 01 Rev. 2 in accordance with FDA regulations, ICH guidelines and 
Good Clinical Practice s. I have carefully read and understand the foregoing protocol and agree that it 
contains all the necessary information for conducting this study safely. I will conduct this study in strict accordance with this protocol, the Code of Federal Regulations, the Health Insurance Portability and 
Accountability Act (HIPAA), and local regulatory guidelines. I will attempt to complete the study within the time designated. I will ensure that the rights, safety  and welfare of subjects under my care are protected. 
I will ensure control of the drugs under investigation in this study. I will provide copies of the protocol and 
all other study -related information supplied by the sponsor to all personnel responsible to me who 
participate in the study. I will discuss this inform ation with them to assure that they are adequately informed 
regarding the drug and conduct of the study. I agree to keep records on all subject information (case report forms, shipment and drug return forms, and all other information collected during the study) and drug 
disposition in accordance with FDA regulations. I will not enroll any subjects into this protocol until IRB 
approval and sponsor approval are obtained. I understand that no deviations from the protocol may be made . 
  
Principal Investigator ’s Name  
  
Principal Investigator ’s Title  
  
Principal Investigator ’s Email Address  
  
Site Address  
 
  
Site Telephone Number  
  
Site Fax Number  
  
   
___________________________________   ____________________________________ 
Principal Investigator ’s Signature      Date  
  
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 5 of 67 
 
 4.0 TABLE OF CONTENTS  
 
1.0 TITLE PAGE  .......................................................................................................................................... 1 
2.0 KEY STUDY PERSONNEL AND FACILITIES  .................................................................................. 2 
3.0 SIGNATURE PAGE  .............................................................................................................................. 3 
4.0 TABLE OF CONTENTS  ........................................................................................................................ 5 
5.0 SYNOPSIS  .............................................................................................................................................. 9 
6.0 STUDY SCHEMATIC  ......................................................................................................................... 18 
7.0 LIST OF ABBREVIATIONS AND TERMS  ....................................................................................... 19 
8.0 INTRODUCTION  ................................................................................................................................ 20 
8.1 Disease Being Treated  ...................................................................................................................... 20 
8.2 Availability and Efficacy of Already Approved Therapies .............................................................. 20 
8.3 Scientific and Statistical Considerations ........................................................................................... 21 
8.4 Justification for use of Placebo  ......................................................................................................... 21 
8.5 Risks and Benefits ............................................................................................................................ 21 
9.0 STUDY OBJECTIVES  ......................................................................................................................... 22 
10.0 INVESTIGATIONAL PLAN ............................................................................................................. 22 
10.1 Study Design and Plan Description ................................................................................................ 22 10.2 Selection of Study Design ............................................................................................................... 23 10.3 Selection of Study Population ......................................................................................................... 24 
10.3.1 Inclusion Criteria...................................................................................................................... 24 10.3.2 Exclusion Criteria .................................................................................................................... 25 
10.3.3 Restrictions During the Study .................................................................................................. 26 
10.3.4 Withdrawal of Subjects from the Study ................................................................................... 27 
10.3.5 Early Termination .................................................................................................................... 28 
10.4 Treatments  ...................................................................................................................................... 29 
10.4.1 Treatments Administration  ...................................................................................................... 29 
10.4.2 Identity of IP ............................................................................................................................ 30 10.4.3 Study Blind .............................................................................................................................. 30 
10.4.4 IP Shipment, Retention and Storage ........................................................................................ 31 10.4.5 Method of Assigning Subjects to Treatment Groups ............................................................... 32 10.4.6 Compliance .............................................................................................................................. 33 
10.5 Study Conduct ................................................................................................................................. 34  
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 6 of 67 
 
 10.5.1 Visit 1 ( Day -14 to Day 1): Screening and Baseline Evaluation  .............................................. 34 
10.5.2 Visit 2 ( Day 28 ± 4 days ): Interim Visit  ................................................................................... 35 
10.5.3 Visit 3: (Day 56 ± 4 days): Int erim Visit  ................................................................................. 36 
10.5.4 Visit 4: (Day 85 ± 4 days) End of Study Visit or Early Termination....................................... 36 
10.6 Study Procedures ............................................................................................................................ 37 
10.6.1 Informed Consent ..................................................................................................................... 37 
10.6.2 Demographics .......................................................................................................................... 37 10.6.3 Medical History........................................................................................................................ 37 10.6.4 Pregnancy Test ......................................................................................................................... 37 
10.6.5 Vital Signs  ................................................................................................................................ 37 
10.6.6 Concomitant Medication  .......................................................................................................... 38 
10.6.7 Dermatologic Assessment ........................................................................................................ 38 
10.6.8 IGA .......................................................................................................................................... 38 10.6.9 PASI ......................................................................................................................................... 38 10.6.10 Application Site Reactions ..................................................................................................... 39 10.6.11 Inclusion and Exclusion Criteria Review ............................................................................... 39 
10.6.12 Randomization ....................................................................................................................... 39 10.6.13 Dispensing IP ......................................................................................................................... 39 
10.6.14 Returning IP ........................................................................................................................... 39 
10.6.15 Subject Dosing Instructions and Diary .................................................................................. 40 10.6.16 Standardized Sunscreen ......................................................................................................... 40 
10.6.17 Health Status/AEs .................................................................................................................. 40 
10.7 AEs/SAEs ....................................................................................................................................... 40 
10.7.1 Definitions ................................................................................................................................ 41 10.7.2 Severity of AEs ........................................................................................................................ 42 10.7.3 Relationship to the IP ............................................................................................................... 42 
10.7.4 AE Documentation ................................................................................................................... 42 
10.7.5 SAE Reporting ......................................................................................................................... 43 
10.7.6 Pregnancies .............................................................................................................................. 46 10.7.7 Quality Complaints .................................................................................................................. 46 
 46 
10.7.9 Rec onc
iliation .......................................................................................................................... 47 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 7 of 67 
 
 11.0 STATISTICAL METHODS  ............................................................................................................... 47 
11.1 Statistical Plan ................................................................................................................................. 47 
11.2 S ample Size Determination  ............................................................................................................. 48 
11.3 Study Populations ........................................................................................................................... 48 
11.3.1 PP Population ........................................................................................................................... 48 11.3.2 Modified Intent- to-Treat (mITT) Population  ........................................................................... 49 
11.3.3 Safety Populations.................................................................................................................... 49 
11.4 Baseline Comparability ................................................................................................................... 49 11.5 Efficacy Endpoints .......................................................................................................................... 50 
11.6 Primary and Secondary Endpoint Analyses .................................................................................... 50 
11.7 Treatment -by-Site Interaction and Pooling of Clinical Sites  .......................................................... 51 
11.8 Safety Analysis ............................................................................................................................... 51 
12.0 REGULATORY OBLIGATIONS  ...................................................................................................... 51 
12.1 Institutional Review Board ............................................................................................................. 51 12.2 Subject Confidentiality ................................................................................................................... 52 12.3 Study Documentation...................................................................................................................... 52 
12.3.1 Protocol .................................................................................................................................... 52 
12.3.2 Informed Consent ..................................................................................................................... 53 
12.3.3 Protocol and Informed Consent Changes ................................................................................. 53 
12.3.4 Source Documents and Case Report Forms ............................................................................. 53 12.3.5 Drug Accountability  ................................................................................................................. 54 
12.3.6 Drug Storage ............................................................................................................................ 54 12.3.7 Retention of Reserve Samples ................................................................................................. 54 12.3.8 Return of Clinical Supplies ...................................................................................................... 55 
12.3.9 Pregnancy and Breastfeeding ................................................................................................... 55 12.3.10 Reporting Safety Information to the IRB ............................................................................... 56 
12.3.11 Record Retention.................................................................................................................... 56 
12.3.12 Study Monitoring and Auditing ............................................................................................. 57 12.3.13 Confidentiality, Use of Information and Publication ............................................................. 60 12.3.14 End of the Trial  ...................................................................................................................... 60 
12.3.15 Clinical Study Report ............................................................................................................. 61  
12.3.16 Te r
mination of the Study  ....................................................................................................... 61 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 8 of 67 
 
  62 
1
4.0 APPENDICES  .................................................................................................................................... 63 
14.1 APPENDIX A: Investigator’s Global Assessment of Disease Severity  ......................................... 63 
14.2 APPENDIX B: Psoriasis Area Severity Index at the Target Lesion Site  ....................................... 64 
14.3 APPENDIX C: Application Site Reactions .................................................................................... 65 
14.4 APPENDIX D: TAZORAC® (tazarotene)  Product Insert .............................................................. 66 
14.5 APPENDIX E: Amendments to the Protocol ................................................................................. 67 
 
  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 9 of 67 
 
 5.0 SYNOPSIS 
 
Protocol Number  0453-01-01 
Title  A Multi -Center, Double -Blind, Randomized, Vehicle -Controlled, Parallel -
Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® 
(Tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle 
Control in the Treatment of Stable Plaque  Psoriasis  
Objectives 1. Evaluate the therapeutic equivalence of the Test product , Tazarotene 
Cream 0.05%  (Fougera Pharmaceuticals Inc. ) to the Reference product, 
TAZORAC® (tazarotene) Cream 0.05%  (Allergan, Inc.)  in the treatment 
of stable plaque  psoriasis. 
2. Demonstrate the superiority of the efficacy of the Test and Reference 
(active) products over that of the  Placebo  in the treatment of stable 
plaque psoriasis. 
3. Compare the safety of the Test, Reference and Placebo products in the 
treatment of  stable plaque psoriasis. 
Sponsor  Fougera Pharmaceuticals Inc.  
Investigational 
Products  • Test:  Tazarotene Cream 0.05% ( Fougera Pharmaceuticals Inc. ) 
• Reference : TAZORAC® (tazarotene) Cream , 0.05% (Allergan, Inc.) 
• Placebo:  Placebo (vehicle)  Cream (Fougera Pharmaceuticals Inc. ) 
Dose and Route of 
Administration  Subjects will be instructed to apply the investigational product  (IP) 
topically, once daily, in the evening, for 84 days ± 4 days (12 weeks). 
Enough cream should be applied (2 mg /cm2) to cover only the lesions with 
a thin film. Hands should be washed thoroughly before and after each 
application. It is recommended that if a bath or shower is taken before 
application, the skin should be dry before applying the cream.  
Treatment Period  84 days (12 weeks) ± 4 days 
Treatment Randomization 1: 1: 1 (Test: Reference: Placebo)  
Subject  Populations Approximately 855 male and non-pregnant female subjects, at least  18 years 
of age  who meet all of the inclusion criteria and non e of the exclusion 
criteria,  will be enrolled in order to obtain  subject  in the modified Intent-
to-Treat (mITT) population and  subject s in the per-protocol (PP) 
population. 
The primary inclusion criteria are : 
• Clinical diagnosis of stable  (at least 6 months)  plaque psoriasis 
involving at least 2% and no more than 20% of Body Surface Area (BSA) not including the scalp and intertriginous areas  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 10 of 67 
 
 • An Investigator 's Global Assessment (IGA) of disease severity of at 
least moderate severity ( Score ≥ 3) as an overall assessment of 
lesions to be treated  
• A minimum plaque elevation of at least moderate severity ( Score ≥ 
3) at the target lesion (the most severe lesion at Baseline ) 
Study Design  A multi-center, double-blind, randomized, v ehicle -controlled, parallel -
group bioequivalence s tudy with clinical endpoints c omparing Tazarotene 
Cream 0.05% to TAZORAC® (tazarotene) Cream , 0.05% and both active 
treatments to a vehicle control in the treatment of stable plaque p soriasis. 
Investigative Sites Approximately 30 sites in the United States  
Study Conduct  Eligible subject s will be randomized in a 1:1:1 ratio to one of the th ree 
treatment  groups (Test, Reference or Placebo) at  Visit 1 . IP will be 
dispensed at Visit 1. Subject s will be instructed to apply  enough cream 
(2 mg/cm2) to cover only the psoriatic lesions with a thin film. The first dose 
will be applied  on the evening of Day 1. The subject will  then continue to  
apply a thin film (2 mg/cm2) of the product once daily, in the evening, to 
cover only psoriatic lesions until the evening before Visit 4 (Day 85 ± 4 
days) . Subject s will attend the following scheduled clinic vis its: 
• Visit 1  - Screening /Baseline: Day -14 to 1 
• Visit 2  - Interim Visit: Day 28 ± 4  days 
• Visit 3  - Interim Visit: Day 56 ± 4  days 
• Visit 4  - End of Study /Early Termination : Day 8 5 ± 4  days 
Efficacy evaluations will be based on dermatological assessments 
performed in the clinic. The primary endpoint is the proportion of subjects 
with treatment success on the IGA at the Week 12 visit (Day 85 ± 4, End of 
Study). S ee Appendix A for IGA scale. 
Inclusion Criteria  1. Male or non -pregnant, non -lactating female,  ≥ 18 years of age with a 
clinical diagnosis of stable  (at least 6 months)  plaque psoriasis. 
2.  
 
3. Females of childbearing potential must not be lactating or pregnant at 
Visit 1 (as confirmed by a negative urine pregnancy test with a 
sensitivity of less than 50 mlU/mL or equivalent units of human 
chorionic gonadotropin) and  
 
Childbearing Potential  
Defined as:  Non-Childbearing Potential  
Defined as:  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 11 of 67 
 
 Evidence of menses in the past 
12 months Post-menopausal, defined as 
women who have been amenorrheic for at least 12 consecutive months, without other known or suspected 
primary cause.  
Amenorrhea for ≥ 12 months, but 
the amenorrhea is possibly due to 
other causes, including prior 
chemotherapy, anti- estrogens or 
ovarian suppression  Sterilized surgically or who are 
otherwise proven sterile (i.e., 
total hysterectomy, or bilateral 
oophorectomy) with surgery at least 4 weeks before Screening. Tubal ligation will not be 
considered a surgically sterile 
method. 
4. 
5. Have c
linical diagnosis of stable  (at least 6 months)  plaque psoriasis 
involving at least 2% and  no more than 20% B SA not including the  
scalp and intertriginous areas. 
6. Have an IGA of disease severity grade of at least  moderate severity 
(score ≥  3 per  Appendix A). 
7. Have a Psoriasis Area Severity Index (PASI)  minimum plaque elevation  
grade of at least  moderate severity (score ≥  3 per Appendix B ) at the 
target lesion site.  The most severe lesion at Baseline  should be identified 
as the target lesion.  
8.  
 
 
 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 12 of 67 
 
 9. Willing to avoid constant sun exposure and the use of tanning booths or 
other ultraviolet light sources during their participation in the study. 
10.  
 
 
Exclusion Criteria  1. Females who are pregnant, breast feeding, planning a pregnancy or do 
not agree to use an acceptable form of birth control throughout the 
study. 
2. Has a current diagnosis of unstable forms of psoriasis in the treatment 
area including guttate, erythrodermic, exfoliat ive or pustular psoriasis.  
3. Has clinically infected psoriasis at Baseline. 
4. In the Investigator s opinion, subject has  other inflammatory skin disease 
in the treatment area that may confound the evaluation of the plaque 
psoriasis (i.e., atopic dermatitis, con tact dermatitis, eczema, tinea 
corporis). 
5. Has presence of pigmentation, extensive scaring, pigmented lesions or 
sunburn in the treatment area which could interfere with the rating of 
efficacy parameters.  
6. Has a history  of psoriasis unresponsive to topical treatments  and/or 
biologic treatments. 
7. Has a history of hypersensitivity or allergy to tazarotene, retinoids, 
and/or any component of the IP (Test, Reference or Placebo). Please 
refer to the Reference Listed Drug Package Insert for the components 
of the IP 
8. Current signs or symptoms of immunosuppression. 
9.  
 
 
 
 
 
 
10. Has treated with any marketed or investigational biologics for psoriasis 
(i.e., infliximab, adalimumab, alefacept, etc.) within 6 months before  
Baseline.  
11. Has been treated with chemotherapy or radiation therapy within  3 
months before  Baseline.  
12. Has treated with any immunosuppressive drugs (i.e., tacrolimus, 
pimecrolimus) or oral retinoids within  2 months before  Baseline.  
13. Has treated with systemic steroids, systemic antibiotics, systemic anti-
psoriatic treatment (i.e. , methotrexat e, cyclosporine, hydroxyurea), 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 13 of 67 
 
 PUVA therapy, ultraviolet -B Therapy  or systemic anti -inflammatory 
agents within 1 month before Baseline .  
 
 
 
 
 
 
 
 
14. Has treated with topical anti -psoriatic drugs (i.e. , salicylic acid, 
anthralin, coal tar, calcipotriene, tazarotene), topical corticosteroids  or 
topical retinoids within 2 weeks before  Baseline . 
15. Inability  to understand the protocol requirements, instructions and 
study- related restrictions, the nature, scope and possible consequences 
of the c linical study.  
16. Receipt of  any drug  and/or IP as part of a research study within  the 30 
days before  Baseline. 
17. Subjects w ho consume excessive amounts of alcohol, abuse drugs, or 
have any social condition  that would , in the Investigator’s opinion, 
compromise compliance with this protocol. 
18. Previou s participation in this study.  
19. Employees of the Investigator or research center or their immediate 
family members.  
Efficacy Endpoints  
 Primary Efficacy Endpoint  
Proportion of subjects with treatment success ( defined as none , minimal  or 
mild disease, a score of 0,  1 or 2 within the treatment area ) on the IGA  at 
the Week 12 visit ( Day 8 5 ± 4, End of Study). 
Secondary Efficacy Endpoint s 
1. Proportion of subjects with  disease severity at the Week 12  visit (D ay 
85 ± 4, End of Study)  consistent with none or minimal , a score of 0 or 
1, with in the treatment area on the IGA, and 
2. Proportion of subjects with target site plaque elevation, scaling  and 
erythema scores of less than or equal to 1on the PASI at the Week 12 
visit ( Day 85 ± 4 , End of Study). 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 14 of 67 
 
 Measures  The following scales will be used for evaluation of Baseline disease 
severity and treatment effect.  
IGA of Disease Severity  
Score  Grade  Definition  
0 None  No plaque elevation above normal skin level; may 
have residual non-erythematous discoloration;  
no psoriatic scale; no erythema  
1 Minimal  Essentially flat with possible trace elevation; faint 
erythema; no psoriatic scale  
2 Mild  Slight but definite elevation of plaque above normal 
skin level; may have up to moderate erythema (red 
coloration); fine scales with some lesions partially 
covered  
3 Moderate  Moderate elevation with rounded or sloped edges to 
plaque; moderate erythema (red coloration); 
somewhat coarse scales with most lesions partially 
covered  
4 Severe Marked elevation with hard, sharp edges to plaque; 
severe erythema (very red  coloration); coarse, thick 
scales with virtually all lesions covered and a rough 
surface  
5 Very  
Severe  Very marked elevation with very hard, sharp edges to 
plaque; very severe erythema  
(extreme red coloration); very coarse, thick scales 
with all lesions covered and a very rough surface  
 
 Subjects with IGA grade of ≥ 3 will be enrolled in the study 
PASI at the Target Lesion Site  
Score  Grade  Erythema  Scaling  Plaque 
Elevation 
0 Clear  No evidence 
of erythema  No evidence of scaling  No evidence of plaques above normal skin level  
1 Almost Clear  Pink discoloration, minimal 
erythema Occasional fine 
scales hardly noticeable  Slight, just discernible elevation 
above normal 
skin level  
2 Mild  Light red coloration Slight but definite roughness, fine Discernible elevation above normal 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 15 of 67 
 
 scale present, no 
cracking  skin level upon 
examination, 
but not pronounced 
3 Moderate Moderate redness, but 
not dark Moderate 
roughness, 
somewhat 
coarse scaling  Definite plaque 
formation with 
rounded/sloped edges to plaque 
4 Severe  Dark red 
coloration Marked 
roughness, coarse/thick 
scaling, cracking 
may be evident Marked 
elevation with hard, distinct 
edges to 
plaque 
5 Very Severe  Very dark red coloration with induration 
present Very thick 
scales covering extensive area severe cracking/fissures 
may be evident Very marked 
elevation, very hard and sharp edges to plaque 
 
Evaluation of Therapeutic Equivalence and Superiority  The primary analyses for evaluating the therapeutic equivalence of the Test and Reference treatments, and the superiority of each active treatment over the Placebo, will be based on the proportion of subject s with treatment  
success  (defined as " none , minimal  or mild disease, a score of 0,  1 or 2, 
within the treatment area") on the IGA  at Week 12  visit (Day 85  ± 4, End 
of Study). 
The statistical analyses for equivalence for binary outcomes for the primary 
and two secondary endpoints will be based on a Y ates’ continuity -corrected 
confidence interval on the Test minus Reference difference (T -R) in 
proportions. Superiority will be tested at the 5% significance level using a 
Cochran- Mantel -Haenszel exact test stratified by clinical site for Test versus 
Placebo and Reference versus Placebo  for the three endpoints . 
Therapeutic Equivalence Analysis  
Therapeutic equivalence will be evaluated for both primary and secondary 
endpoints using the PP population , with results in the mITT population 
being supportive . For the dichotomized primary endpoint (proportion of 
treatment success), if the 90% confidence interval (with Yates’ Correction 
Factor) of the difference between the proportion of subject s considered a 
“treatment success” in the Test and the Reference treatment groups at Week 
12, compared to Baseline, is contained within the pre -defined equivalence 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 16 of 67 
 
 limits [ -20%, +20%], then therapeutic equivalence will  be considered to 
have been supported for the endpoint. The same statistical approach will be 
conducted for  analysis of  the two dichotomized secondary endpoints  in the 
PP and mITT populations. 
To declare therapeutic equivalence of the Test product to the Reference 
product, therapeutic equivalence must be demonstrated for only the primary 
endpoint in the PP population . 
Superiority to Placebo Analysis 
The primary measure of superiority will be evaluated using the mITT 
population and last observation carried forward ( LOCF ) for missing 
efficacy values. The results in the PP population will be considered 
supportive. The superiority of the Test and Reference products over Placebo 
will be concluded for the primary endpoint if the proportion of treatment 
success at Week 12  is statistically superior to Placebo ( p < 0.05, two- sided) 
using the mITT population and LOCF . The same statistical approach will 
be conducted for analysis of  the two dichotomized secondary endpoints  in 
the mITT  and PP populations. 
To declare superiority  of the Test and Reference products over Placebo, 
their superiority  must be demonstrated for only  the primary endpoint  in the 
mITT population. 
Safety Analysis  Adverse events (AEs) will be classified using standard MedDRA 
terminology Version 18.1 or higher and summarized by treatment group. 
Summary tables comparing the type, date of onset, date of resolution, 
incidence, severity, relationship to the IP, outcome and action taken will be 
prepared by treatment group. Should sufficient data exist, AE frequencies 
will be compared among treatments using Fisher’s exact test or a similar 
test. Application site reactions  (erythema, dryness, burning/stinging, 
erosion, edema, pain, itching) recorded at each visit will be compared 
among treatment groups. A des criptive analysis comparing the application 
site reactions for each treatment group will be created.  
Concomitant medication use during the treatment period will be tabulated 
by subject . 
Signs and symptoms of psoriasis will not be considered AEs, unless in the 
Investigator ’s opinion, they have increased in frequency and/or severity to 
such an extent that the Investigator /subject  considers that it is in the 
subject’s best interest to be dropped from continued participation in the 
study and given alternative t herapy for their condition.  
All randomized subject s who received IP will be included in the 
comparative safety analysis.  
Sample Size Determination Sample size calculations were performed using  
For the primary endpoint analysis , the rate of treatment success for the 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 17 of 67 
 
 Reference treatment after 12 weeks of treatment is expected to be 
approximately  in the PP population. Assuming that the rates of 
treatment success for Test  and Reference treatments are the same, a sample 
size of  subject s in each active group in the PP population will provide 
approximately  power to demonstrate therapeutic equivalence (i.e., the 
90% confidence interval (Yates’ continuity -corrected) of the absolute 
difference between the Test and Reference rates  of treatment success  is 
within a defined equivalence range [ -20% to + 20%]).  
The rates of treatment success for the Placebo and active treatment groups 
after 12 weeks of treatment are assumed to be approximately  and at 
least  respectively, in the mITT population. Using a 1:1 (active: 
placebo) randomization scheme, and assuming the conversion rate from 
mITT to PP population will be about   subject s in each treatment 
group (Test, Reference and Placebo) of the mITT population will provide at 
least  power  to demonstrate superiority of active over Placebo  at the  
significance level (p < 0.05, two-sided continuity -corrected Z -Tests and a 
pooled response rate for the standard error of the difference in proportions) . 
Under the above assumptions, the overall study power to demonstrate 
therapeutic equivalence and superiority is estimated to be at least . To 
allow for approximately  of subject s who may drop out from the study 
or are otherwise non- evaluable, up to 855 subject s may be randomized to 
obtain  subject s in the mITT population (i.e.,  per treatment arm).  
  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 18 of 67 
 
 6.0 STUDY SCHEMATIC  
 
PROCEDURE  VISIT 1  
(Day -14 to 
1) 
Screening/  
Baseline   VISIT 2  
(Day 28 
± 4 Days)  
Interim Visit  
 VISIT 3  
(Day 56 
± 4 Days) 
Interim Visit  
 VISIT 4  
(Day 85 
± 4 Days)*  
End of Study / 
Early 
Termination  
Informed Consent X‡    
Medical History/  
Demographics  X‡    
Pregnancy Test†  X‡ X X X 
Vital Signs  X‡   X 
Dermatologic Assessment  X‡    
IGA X‡ X X X 
PASI Assessment  X‡ X X X 
Application Site Reactions  X X X X 
Inclusion/Exclusion  Criteria 
Review   X‡    
Concomitant Medication  X‡ X X X 
Randomization X    
Dispense IP X X** X**  
Return of IP    X** X** X 
Dispense Subject 
Diary /Supplies X X X  
Collect /Review Subject  Diary   X X X 
Adverse Events   X X X 
Discharge from Study    X 
* Dosing regimen is once daily in the evening for 84 days (Day 1 to Day 84) through the evening before Visit 4 (Day 85 ± 4 ) 
** If applicable, based on use of previously dispensed product. 
† For females of childbearing potential  
‡ Procedures performed as part of the screening assessment, before randomization 
  
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 19 of 67 
 
 7.0 LIST OF ABBREVIATIONS AND TERM S 
AE Adverse Event  
ADR  Adverse Drug Reaction  
ADaM  Analysis Dataset Model  
ANOVA  Analysis of Variance  
BSA  Body Surface  Area  
C Celsius  
CDER  Center for Drug Evaluation and Research  
CDISC  Clinical Data Interchange Consortium  
CFR  Code of Federal Regulations  
CI Confidence Interval  
cm Centimeter  
CRO  Clinical Research Organization  
eCRF  electronic Case Report Form  
eCTD  electronic Common Technical Document  
F Fahrenheit  
FDA  
g  Food and Drug Administration  
Gram  
GCP  Good Clinical Practices  
HIPAA  Health Insurance Portability and Accountability Act  
ICF  Informed Consent Form  
ICH International Conference on Harmoni sation  
IGA Investigator ’s Global Assessment  
IP Investigational Product  
IRB Institutional Review Board  
IRT Interactive Response Technology  
IUD Intrauterine Device  
LOCF  
LPPV  Last Observation Carried Forward  
Local Person for Pharmacovigilence  
MedDRA  
mg Medical Dictionary for Regulatory Activities  
Milligram  
mITT  modified Intent -to-Treat  
ml milliliter  
NDA  New Drug Application  
OGD  Office of Generic Drugs  
OHRP  Office of Human Rights Protection  
OTC  Over -The-Counter  
PASI  Psoriasis Area Severity Index  
PD Protocol Deviation  
PP Per-Protocol  
RLD  Reference Listed Drug  
SADR  Serious Adverse Drug Reaction  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SAS Statistical Analysis Software  
SDTM  Study Data Tabulation Model  
  
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 20 of 67 
 
 8.0 INTRODUCTION  
8.1 Disease Being Treated  
Psoriasis is an immune (T-cell)-mediated inflammatory skin disease that affects approximately 2% of 
the western  population.1 The most common type of psoriasis is plaque psoriasis, which is characterized 
by the presence of raised, thickened red lesions that are covered by silvery white scales, most commonly 
seen on the knees and/or elbows. Although there are reports implicating a genetic association with the 
disea se, there are also studies that have established a set of psoriasis triggers including stress, 
medications (such as lithium, antimalarials, indomethacin, quinidine  and beta blockers), injury or 
infection. The condition is considered chronic although the fr equency and severity of outbreak in an 
individual can fluctuate without apparent cause.1-3 
Treatment of plaque psoriasis depends on the severity of the condition, previous treatment regimens 
and personal preference of the subject . For mild to moderate plaque psoriasis, topical treatments and 
phototherapy are the preferred treatment modalities. For more severe c ases, oral or injectable systemic 
therapy may be warranted; however, the side effect profiles of these products limit their use.  
Psoriasis is typically described as mild, moderate or severe and by assessing the percentage of body surface area  (BSA)  affecte d and covered by psoriasis lesions. Several scale systems have been 
developed and many are in use in the clinical setting; however , a severity scale, despite being a 
convenient scoring system, does not capture the true burden of psoriasis for many patients. Psoriasis is associated with a broad range of medical and psychosocial comorbidities that erode quality of life of 
the patients. Subjects selected for this study suffer from plaque psoriasis of at least moderate severity 
and an IGA of 3 or more. 
8.2 Availabi lity and Efficacy of Already Approved Therapies  
Treatment of plaque psoriasis depends on the severity of the condition, previous treatment regimens 
and personal preference of the subject . Psoriasis treatments historically include topical creams, sprays, 
lotions and foams. Examples of marketed products include corticosteroids (Topicort
®, Clobex™), 
Vitamin A & D derivatives (T azorac®, Dovonex®), NSAIDs (salicylic acid), etc. For more severe cases, 
systemic therapy (methotrexate, oral retinoids, UV light, biologics , etc.) may be warranted; however, 
the side effect profiles of these products limit their use.1,2,4-6 
Tazarotene is one of a class of drugs known as the acetylenic retinoids.  Psoriasis is a chronic immune -
mediated disease that is characterized by the hyperproliferation  and abnormal differentiation of 
keratinocytes and by inflammation. The epidermal changes associated with psoriasis may be due to the infiltration of inflammatory T lymphocytes and the release of cytokines in response to antigenic stimulation. Tazarotene is a retinoic acid receptor -specific retinoid with demonstrated efficacy in the 
topical treatment of psoriasis. Tazarotene down- regulates markers of keratinocyte differentiation, 
keratinocyte proliferation  and inflammation. The drug also up- regulates three novel genes TIG -1 
(tazarotene -induced gene -1), TIG -2 and TIG-3, which may mediate an antiproliferative effect. The 
effect of tazarotene on these markers is probably a direct effect on gene expression rather than an 
indirect effect associated with disease improvement. 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 21 of 67 
 
 8.3 Scientific and Statistical Considerations  
Tazarotene has low systemic absorption and rapid elimination from semi -solid topical formulations 
of TAZORAC®. In a multiple -dose study with a once  daily dose of tazarotene cream, 0.1% 
administered for 14 consecutive days to nine psoriatic subject s, mean peak plasma concentrations 
of 2.31 ng/mL occurring 8 hours  after the final dose were observed for  the active metabolite of 
tazarotene (tazarotenic acid ).7 The 21 Code of Federal Regulations Sections 320.24 (Revised 
April  1, 2014) requires that in- vivo pharmacokinetic testing in humans is the preferred method in 
evaluating therapeutic  equivalence.  However , circumstances for which measurement of the active 
moieties in biological fluids is not possible  or provides low concentrations, a pharmacodynamic 
response study indicative of clinical safety and efficacy can be considered.8-10 Based on the low 
systemic bioavailability of tazarotene from the topical cream product , a comparative clinical 
efficacy study is considered the most appropriate method to evaluate the therapeutic equivalence  
of two tazarotene topical cream, 0. 05% formulations. 
 
  
 
  
 
8.4 Justification for use of Placebo  
A Placebo group is included to confirm the sensitivity of the study and minimize the possibility of 
a false positive result of therapeutic equivalence. Therefore, in addition to demonstrating 
therapeutic equivalence between  Test and Reference products, both active products must show 
statistical superiority to the Placebo.11,12 
Eligible subject s will have a 33.33% chance of being randomized to Placebo (1:1:1 randomization 
scheme of Test: Reference: Placebo ).  
  
 
 
 
 
 
8.5 Ri
sks and Benefits  
The risks and benefits to subject s enrolled in clinical research studies that include a Placebo 
treatment group must be carefully considered based on three main criteria, namely: the disease being treated, the availability, efficacy and safety of approved therapies, and the scientific and 
statistical requirements of the desired outcome of the research study. The Office of Human Rights Protection (OHRP), a Division of the United States Federal Government’s Department of Health 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 22 of 67 
 
 and Human Services, has issued a detailed  guidebook to IRBs  that includes discussion on the use 
of placebos in clinical studies.13 
Randomized subject s will be enrolled in the study for 85 ± 4 days . Although the potential for any 
drug- related side effects of significance occurring during the study is low, the risk is higher in the 
two active treatment groups than in the Placebo group.  Topical application of Tazarotene can lead 
to drug -related effects, mainly affecting the application sites: skin itching, irritation, dryness and 
burning or pain sensation represent the most common side effects. 
All subject s enrolled in this study will receive Investigator  evaluation of their condition over 85 
days. In addition, the subject  will be paid for their participation, and any payments will be reviewed 
by the IRB and disclosed to the subject, via the informed consent form (ICF).  
9.0 STUDY OBJECTIVES  
The objectives of this study are to:  
1. Evaluate the therapeutic equivalence of the Test product, Tazarotene Cream  0.05% (Fougera 
Pharmaceuticals Inc. ) to the Reference product, TAZORAC® (tazarotene)  Cream , 0.05% 
(Allergan ) in the treatment of stable plaque psoriasis. 
2. Demonstrate the superiority of the efficacy of the Test and Reference (active) products over that of 
Placebo in the treatment of stable plaque psoriasis . 
3. Compare the safety of  the Test, Reference and Placebo products in the treatment of stable plaque  
psoriasis. 
10.0 INVESTIGATIONAL PLAN 
10.1 Study Design and Plan Description  
This multi -center , double -blind, randomized, vehicle -controlled, parallel-group, bioequivalence 
clinical  study has been designed to evaluate the efficacy and safety of a generic tazarotene c ream  0.05% 
(Fougera Pharmaceuticals Inc. ) compared to the FDA Reference Listed Drug (RLD) TAZORAC® 
(tazarotene ) Cream  0.05% ( Allergan ) in subject s with a clinical diagnosis of stable plaque psoriasis  of 
at least moderate severity . Additionally, both the Test product and Reference (i.e., the RLD)  products 
will be tested for superiority to a Placebo. Subject s with confirmed  stable  plaque psori asis will apply 
the investigational product  (IP) once daily , in the evening , to psoriatic lesions for 84 ± 4 days (12 
weeks).  
Before any study -specific procedures are performed, all subject s will read and sign the IRB -approved 
ICF. 
Each site will develop an individualized recruitment plan to collectively enroll approximately  855 
eligible subject s, 18 years of age and older , with a clinical diagnosis of stable plaque psoriasis and 
meet ing the inclusion/exclusion criteria. Subjects  will be randomized to one of the three IPs as follows:  
• Test: Tazarotene Cream , 0.05% (Fougera Pharmaceuticals Inc. ) 
• Reference:  TAZORAC® (tazarotene) Cream , 0.05%  (Allergan , Inc.) 
• Placebo:  Placebo (vehicle) Cream  (Fougera Pharmaceuticals Inc. ) 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 23 of 67 
 
 Subject s will attend the following scheduled clinic visits:  
• Visit 1  - Screening /Baseline: Day -14 to Day 1 
• Visit 2  - Interim Visit: Day 28 ± 4  days 
• Visit 3  - Interim Visit: Day 56 ± 4  days 
• Visit 4 - End of Study /Early Termination : Day 85 ± 4  days 
At Visit 1, eligible subjects will be ra ndomized to the Test, Reference or Placebo product in a 1:1:1 
ratio using the  system , which is an interactive response technology  (IRT) system provided 
by the IRT provider . Study subject s will be provided with  of IP.  may be 
dispensed to the subject at the discretion of the Investigator  if the subject has a high BSA affected with 
plaque psoriasis at the time of dispensation that would warrant additional product. At Visit 2  and Visit 
3, subject s who continue to be eligible for continuation in the study  can be dispensed   
, as needed based on the subject's current BSA  affected  and the amount of IP 
remaining from the tube(s) previously dispensed. Further, any empty tubes will be collected at these 
visits. At Visit 4, all tubes will be collected (used and unused). A subject may return for an Unscheduled 
Visit at any time, should they require a resupply of IP (i.e. , tube lost; all IP used between visits).  It is 
estimated that approximately  tubes, but up to  tubes may be needed to dose a subject with high BSA  
involvement (~20% B
SA) for the treatment period (depending upon their treatment response over the 
12 w
eeks). Subjects with less BSA  involvement will need significantly less IP (approxi mately  to  
tubes). 
The day 
that the subject administers their first dose of IP will be considered Day 1.  
 
 
 
For all other subje cts, the first dose (Day 1) of IP 
will be applied on the evening of Visit 1. The s ubject  will be instructed to apply  enough cream (2 mg/cm
2) to cover only the psoriatic lesions 
with a thin film  (2 mg/cm2) once daily, in the evening, until the evening befor e Visit 4 (Day 85 ± 4 
days).There will be no application of the product on the day of the End of Study visit. 
Efficacy evaluations will be based on dermatological assessments in the clinic. The primary statistical 
analysi s of interest is the (1) proportion of subject s with treatment success (defined as none, minimal  
or mild disease, a score of 0,  1 or 2, within the treatment area ) on the Investigator’s Global Assessment 
(IGA) at the Week 12 visit. The secondary analyses are (1) proportion of subje cts with disease severity 
at the Week 12 visit consistent with none or minimal , a score of 0 or 1, within the treatment area on the 
IGA, and (2) proportion of subjects with target site plaque elevation, scaling, and erythema sc ores of 
less than or equal to one on the PASI at the Week 12 visit. 
10.2 Selection of Study Design  
This protocol is designed based on studies conducted as a part of the NDA  (21-184) for TAZORAC® 
Cream, 0.05% and the FDA draft guidance for tazarotene cream 0.05%, released in April , 2011.14 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 24 of 67 
 
 Statistical analyses of the clinical data will be based on recommendations in the FDA guidance or 
communications with the Office of Generic Drugs ( OGD)/FDA.9,15 
10.3 Selection of Study Population 
10.3.1  Inclusion  Criteria  
1. Male or non- pregnant, non- lactating female, ≥ 18 years of age with a clinical diagnosis of stable 
(at least 6 months) plaque psoriasis.  
2.  
3. Females of childbearing potential must not be lactating or pregnant at Visit 1 (as confirmed by 
a ne
gative urine pregnancy test with a sensitivity of less than 50 mlU/mL or equivalent units 
of human chorionic gonadotropin) and  
Childbearing Potential 
Defined as:  Non-Childbearing Potential 
Defined as:  
Evidence of menses in the past 12 months Post-menopausal, defined as women who 
have been amenorrheic for at least 12 consecutive months, without other known or suspected primary cause.  
Amenorrhea for ≥ 12 months, but the amenorrhea is possibly due to other causes, including prior chemotherapy, anti-estrogens or ovarian suppression  Sterilized surgically or who are otherwise proven sterile (i.e., total hysterectom y, or 
bilateral oophorectomy) with surgery at least 4 weeks before  Screening. Tubal ligation 
will not be considered a surgically sterile method. 
4. 
5. Have clinical diagnosis of stable (at least 6 months) plaque psoriasis involving at least 2% and  
no more than 20% B SA not including the scalp and intertriginous areas. 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 25 of 67 
 
 6. Have an I GA of disease severity grade of at least moderate severity (score ≥ 3 per Appendi x 
A). 
7. Have a Psoriasis Area Severity Index (PASI) minimum plaque elevation grade of at least 
moderate severity (score ≥ 3 per Appendix B) at the target lesion site. The most severe lesion at Baseline should be identified as the target lesion.  
8.  
 
 
 
9. Willing to avoid constant sun exposure and the use of tanning booths or other ultraviolet light 
sources during their participation in the study. 
10.  
 
10.3.2  Exclusion Criteria  
1. Females who are pregnant, breast feeding, planning a pregnancy or do not agree to use  an 
acceptable form of birth control throughout the study. 
2. Has a current diagnosis of unstable forms of psoriasis in the treatment area including guttate, 
erythrodermic, exfoliative  or pustular psoriasis.  
3. Has clinically infected psoriasis at Baseline. 
4. In the Investigators opinion, subject has other inflammatory skin disease in the treatment area 
that may confound the evaluation of the plaque psoriasis  (i.e., atopic dermatitis, contact 
dermatitis, eczema, tinea corporis) . 
5. Has presence of pigmentation, exten sive scaring, pigmented lesions or sunburn in the treatment 
area which could interfere with the rating of efficacy parameters.  
6. Has a history of psoriasis unresponsive to topical treatments and/or biologic treatments.  
7. Has a history of hypersensitivity or allergy to tazarotene, retinoids, and/or any component of 
the IP (Test, Reference or Placebo). Please refer to the R LD Package Insert for the components 
of the IP . 
8. Current signs or symptoms of immunosupression. 
9.  
 
 
 
 
10. Ha
s tre
ated with any marketed or investigational biologics for psoriasis (i.e., infliximab, 
adalimumab, al efacept, etc.) within 6 months before Baseline. 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 26 of 67 
 
 11. Has been treated with chemotherapy or radiation therapy within 3 months before Baseline. 
12. Has treated with any immunosuppressive drugs (i.e., tacrolimus, pimecrolimus) or oral 
retinoids within 2 months before Baseline.  
13. Has treated with systemic steroids, systemic antibiotics, systemic anti -psoriatic treatment (i.e., 
methotrexate, cyclosporine, hydroxyurea), PUVA therapy, ultraviolet -B Therapy or systemic 
anti-inflammatory agents within 1 month before Baseline.  
 
 
 
 
 
 
14. Has treated with topical anti- psoriatic drugs (i.e., salicylic acid, anthralin, coal tar, 
calcipotriene, tazarotene), topical corticosteroids or topical retinoids within 2 weeks before 
Baseline.  
15. Inability to understand the protocol requirements, instructions and study- related restrictions, 
the nature, scope and possible consequences of the clinical study. 
16. Receipt of any drug and/or IP as part of a research study within the 30 days before Baseline.  
17. Subjects who consume excessive amo unts of alcohol, abuse drugs, or have any social condition 
that would compromise compliance, in the Investigator’s opinion, with this protocol. 
18. Previous participation in this study.  
19. Employees of the Investigator or research center or their immediate family  members.  
10.3.3  Restrictions  During the Study  
The following concomitant medications, products or procedures will not be allowed while enrolled in the study. 
• Use of the following topical products on or near the treatment area:  
o Moisturizers  
o New brands of Make-up 
o Creams, ointments , lotions, powders 
o Topical Corticosteroids 
• Topical or systemic anti -psoriatic  treatments (e.g., anthralin, coal tar, tazarotene, retinoids, 
tacalcitol, inflixamab, adalumumab, alefacept, PUVA therapy, UVB therapy , salicylic acid , 
calcipotriene ) 
• Systemic corticosteroids or s ystemi
 c steroids, systemic anti -inflammatory agents or 
immunosuppressive drugs.  
 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 27 of 67 
 
  
 
 
 
 
• Photos
ensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, 
sulfonamides) 
• More tha n 10,000 IU/day of Vitamin A supplements 
• Initiation or changes to non- antipsoriatic concomitant medication that could affect psoriasis 
(e.g., beta blockers, lithium) during the study 
• The use of tanning booths, sun lamps , non- prescription ultraviolet light sources  or excessive 
sun exposure 
• Phototherapy 
• Application of IP  to unaffected skin  
The treated areas should not be bandaged, covered or wrapped as to be occlusive. The use of 
hormonal contraceptives should not be initiated, changed or stopped during the s tudy. Subject s 
should be instructed to m inimize exposure to natural sunlight  and to use study provided sunscreens 
of at least SPF 15 and wear protective clothing during the day . Subjects should not allow the IP  to 
come in contact with the eyes, eyelids or mouth, should not use IP  on skin that has eczema, and to 
always wash hands thoroughly after application of IP . 
Subjects will be questioned about all prescription and over-the-counter (OTC) concomitant 
medication use (including vitamins or nutritional supplements) at each study visit. All concomitant 
medications will be recorded in the subject’s source documents. Any subject who has violated any of the listed restrictions may be discontinued from the study. If discontinued, all End of Study/Early 
Termination procedures (Visit 4 procedures) should be performed. 
10.3.4  Withdrawal of Subject s from the Study  
Subject s will be advised that they are free to withdraw from the study at any time. Additionally, 
the sponsor may cease the study at any time.  If necessary, the Investigator  may withdraw a subject  
from the study to protect the health of that subject . The clinical study report will include all reasons 
for early withdrawals.  
Reasons for rem oval may include the following:  
• Subject withdraws consent for any reason  
• Subject’s condition has worsened to the degree that the Investigator  feels it is unsafe for 
the subject to continue in the study  
• Lack of treatment effect  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 28 of 67 
 
 • Significant adverse event ( AE) that could affect the safety of the subject  or the validity of 
evaluation of the subject ’s clinical state to an extent considered significant by the 
Investigator  
• Subject’s IP becomes unblinded 
• There is a protocol deviation that, in the Investigator’ s, Medical Monitor’s  or Sponsor’s  
opinion, would compromise the safety of the subject or integrity of the data  
• The subject is lost to follow -up. The Investigator  will document efforts to attempt to reach 
the subject at least twice by telephone and by a certif ied follow -up letter before considering 
that the subject as lost to follow -up 
• Pregnancy  
• Administrative reasons  
• Other (If the reason for withdrawal is not listed, ‘Other’ will be specified and the reason 
noted) 
Subject s who withdraw or are removed from the study will not be replaced. The Investigator may 
refer the subject for appropriate care if the subject withdraws due to safety concerns, as applicable. 
All subject s who are randomized will be included in the safety monitoring tabulating all AEs 
experienced after dosing  until withdrawal from the study . 
10.3.5  Early Termination 
If a subject  terminates from the study early, all efforts will be made to complete Visit 4 study 
procedures , obtain any outstanding data and collect all  IP. For early termination , the Investigator  
shall fully document the reason for early termination and the date of removal. 
In the event that a subject discontinues from the study at any time due to an AE, the reason for 
discontinuation, the nature of the event and its clinical course must be fully documented. For such 
a subject, the Investigator  should follow the subject until the AE has resolved, has become clinically 
insignificant, is stabilized , is confirmed to be ongoing at the end of the study , or the subject is lost 
to follow -up. Should a serious adverse event (SAE) be noted, procedures stated in section 10.7.4 
must be followed. Should pregnancy be noted, procedures stated in section 10.7.6 must be followed.  
Subject s who discontinue early because of lack of treatment effect aft er completing four weeks of 
treatment will be included in the per-protocol ( PP) population as treatment failures  provided they 
had no significant protocol deviations  (PDs) . Any PD that would compromise the  integrity of the 
data will be considered significant.  
Subject s who discontinue early  due to worsening  condition and require alternate or supplemental 
therapy for the treatment of their plaque psoriasis during the study should be discontinued, included 
in the PP population anal ysis as treatment failures (provided they had no significant PDs during 
their time of study participation ), and referred for effective treatment outside of the study.  
Subjects  who discontinue early for reasons besides lack of treatment effect or worsening of 
condition should be excluded from the PP population, but included in the modified Intent- to-Treat 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 29 of 67 
 
 (mITT ) population using the l ast observation carried forward (LOCF), provided they administered 
at least one dose of randomized IP  and completed at least one post -dose evaluation . 
10.4 Treatments  
10.4.1  Treatments Administration  
At Visit 1, eligible subj ects will receive  of 
randomized IP (Test , Reference o r 
Placebo).  may be dispensed to the subject at the discretion of the Investigator  if the 
subject has a high BSA affected with plaque psoriasis at the time of dispensation that would warrant 
. Enough IP should be dispensed to allow the subject to dose daily until the next 
scheduled visit.  
At Visit 
2 and Visit 3, subjects who continue to be eligible for continuation in the study  can be 
dispensed , as needed based on the subject's current BSA and 
the amount of IP remaining from the tube(s) previously dispensed. Further, any empty tubes will 
be collected at these visits. At Visit 4, all tubes will be collected (used and unused). A subject may return for an Unscheduled V isit at any time, should they require a resupply of IP (i.e., tube lost; all 
IP used between visits ; tube significantly damaged [became punctured] ). 
The subject will be instructed on when to apply their first dose of IP, which will be considered Day 1. F
emales of childbearing potential must administer their first dose (Day 1)  
 
 
 For 
all other subjec ts, the first dose (Day 1) of IP will be applied 
on the evening of Visit 1. 
Subject s will be instructed to a pply enough cream (2  mg/cm2) to cover only the lesions with a thin 
film.  If a bath or shower is taken before application, the skin should be dry bef ore applying the 
cream. Subject s will be instructed to apply the medication once daily , in the evening  and to wash 
hands thoroughly before and after each application . The first dose will be applied  on the evening 
of Day  1. The subject will then continue to apply a thin film  (2 mg/cm2) of the product once daily, 
in the evening, to cover only psoriatic lesions until the evening before Visit 4 (Day 85 ± 4  days).  
The amount of IP required for each subject will vary greatly based on the subject's BSA affected 
with psoriasis at Baseline, as well as their rate of improvement or disease worsening  over the course 
of the study. For subjects with BSA involvement close to 20%  at Baseline , it is estimated that up 
to approximately  may be required for each subject to dose for the full 
duration of the study (84 days)  depending upon their treatment response . Significantly less IP would 
be required for subjects with BSA involvement close to 2%  (approximately ). Therefore, 
the amount of IP dispensed to each subject will be dependent upon their BSA involvement  at 
Baseline and as the study progresses, at the discretion of the Investigator . Subject kits will each 
contain  of IP and will be randomized using the  system. After initial 
assignment of the first kit, additional kits of IP may be assigned to the subject as needed for dosing 
and/or to replace a missing tube and/or significantly damaged tube (i.e., punctured), also using the 
 system.   
 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 30 of 67 
 
  
 
At ea
ch visit, the subject  will be provided with a dosing diary in which they will be required to 
record the date of Day 1, all dosing dates and times and any missed doses. Each  diary should be 
returned at the following visit so that the study staff may check compliance  and file in the subject ’s 
source documentation. 
10.4.2  Identity of IP 
The following products will be used in the study: 
• Test: Tazarotene Cream 0.05% ( Fougera Pharmaceuticals Inc. ) 
• Reference : TAZORAC® (tazarotene ) Cream  0.05% ( Allergan , Inc.) 
• Placebo : Placebo (vehicle) Cream  (Fougera Pharmaceuticals Inc. ) 
10.4.3  Study Blind  
The sponsor, clini cal research organization ( CRO ), Investigator , staff at the study site, study 
monitors, and data analysis/management personnel will be blinded to the subject’s treatment  
assignment. The subject  will be requested not to discuss the appearance of the IP tube with the 
Investigator  or study staff outside of the . The 
tubes of Test, Reference and 
Place
bo products will be blinded with identical outer cartons and labels.  This will allow the study 
to be conducted under double -blind conditions (i.e., such that neither the subject  nor the 
Investigator  or study staff members will know the identity of the subject ’s treatment).  
Each study
 site will have an  is blinded to the 
treatment arm that each subject has been randomized to.  
 
 
 
 
 
 
To ensure that information that could potentially bias handling of data is not disclosed, access to 
the master randomization code will be extremely limited. A sponsor representative who is not 
involved in clinical development or the study conduct will provide initial approval of the final code 
to  upon code generation. A member of the sponsor Pharmacovigilence department will have 
access to the code in case of a safety emergency and in order to expedite FDA reporting, if 
applicable. Otherwise , the packaging company  will hold the master 
randomization code until after database lock.  No parties (CRO, clinical sites or sponsor) involv ed 
in the conduct of the study will have access to the master randomization code until after database 
lock.  
Breaking the blind  must be considered only when knowledge of the treatment assignment is deemed 
essential by the Investigator  for the subject's care.  Whenever possible, if the Investigator  feels that 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 31 of 67 
 
 the subject should be unblinded, the Investigator  should contact the  Medical Monitor  to 
discuss the circumstances and come to an agreement before breaking the blind. If the  
Medical Monitor  cannot be reached, then the  or 
designee should be contacted before unblinding.  staff will notify the sponsor if they have 
received any requests to break the blind.  This process will be documented, shared with the sponsor 
and filed. 
CRO Contacts  
 
Cell P
hone:  
Phone:  
Fax:  
Email:  
Or: 
 
 
Phone:  
Fax:  
Email:  
 
If a
 decision is made to unblind the subject, the Investigator  will contact the  
 telephone number for the subject's treatment ass ignment information and document the 
process in the subject's source documentation.  The  unblinding telephone number is available 
24 hours a day. 
 
 
In 
the event the blind is broken for any reason, the  Investigator will notify   as soon as 
possible , preferably within 24 hours, in writing with the details of the occurrence.   staff will 
notify the sponsor.  
At the conclusion of the study, after the database has been locked, each site will be sent a sealed 
envelope containing the full study randomization scheme that should be retained with the study documents in the event of an FDA Inspection. 
10.4.4  IP Shipment, Retention and Storage  
The IP will be shipped to each Investigator’s site from , a centralized 
distribution center . Upon receipt of the IP, the Principal Investigator  (or designee ), must 
immediately inventory the material and confirm receipt with the sponsor, per the instructions 
included in the shipment.  
 
 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 32 of 67 
 
 The Principal Investigator  at each site will then  ensur e that all IP is stored in a locked, secure 
location, with access limited to the Investigator  and his/her designee(s) .  
 All IP will be stored at 20°C to 25°C 
(68°F to 77 ºF), with excursions permitted from -5°C to 30°C (23ºF to 86ºF). The temperature of 
the storage location must be monitored on a daily basis and any excursion beyond the required 
temperature storage range should be reported to the sponsor . An accurate inventory of the IP over 
the course of the study (i.e., dispensed and returned)  will be maintained in accordance with federal 
regulations. 
Initial supply quantities will be based on each site’s projected enrollment quantities. Re supply  w ill 
be conducted as needed based on remaining in -house supply and continued enrollment projections. 
Multiple full blocks of IP will be included in every shipment to the Investigator .  
  
 
  
 
  
 
Once  ha
s not ified the site that they may return the  IP, all unused tubes /kits and empty or 
partially used tubes /kits, other than those randomly selected for retention samples , will be returned 
to the sponsor ( or designee ). It is important that retention samples not be returned to  the 
sponsor or the packaging company during or at the end of the study. Sufficient IP must be retained 
among  the sites participating in the study to meet the sample retention requirements as outlined by 
the FDA.16 
10.4.5  Method of Assigning Subject s to Treatment Groups  
The IP will be randomized, packaged and blinded by an  
. The randomization code will be generated  using a  validated computer program. 
 
 Each site will receive 
multiple, full blocks of IP in each delivery. The quantity received  may vary. 
The IP will be  
 
  
Ove
r the course of the study, additional kits may be 
assigned to the subject using , as needed as determined at the discretion of the 
Investigator , based on the  amount of BSA that remains to be treated . For subjects with BSA 
involvement close to 20% at Baseline, it is estimated that approximately  tubes, but up to  tubes, 
may be required for each subject to dose for the full duration of the study (84 ± 4  days) depending 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 33 of 67 
 
 upon thei r treatment response. Significantly less IP would be required for subjects with BSA 
involvement closer to 2% (approximately ). Therefore, the amount of IP dispensed to 
each subject will be dependent upon their BSA involvement at Baseline and as  the study progresses, 
at the discretion of the Investigator. Each subject will maintain the same treatment assignment 
throughout the study. 
Randomization will be pre -planned according to a computer -generated randomization scheme. The 
randomization code will be retained within  which is maintained by  
.  will also retain the kit boxes numbers supplied to each site and the kit boxes 
numbers that have been selected for retention and are therefore unavailable for dispensing to 
subjects.  
Each kit and tube will be labeled and contain a unique identifying number s.  
 
 
 
 
 
 
Upon confirmation of subject eligibility, the subject’s information (i.e., subject’s initials, date of 
birth, etc.)  will be entered into , and the system will assign  a  
number to the subject based upon a .  w ill then assign the 
subject a  in a blinded fashion  at Visit 1 . This kit box number will 
correspond to a specific treatment group within ; however , the treatment group will be 
unknown to the Investigator , the CRO, the sponsor and the subject. The site will record the 
randomization number and kit box number in the subject’s source documentation and drug dispensing log. The  will then dispense   
 
 At Visit 2 and/or  Visit 3 
and/or an Unscheduled  Visit, additional IP may be dispensed to the subject, as needed . The 
 
dispense it to the subject and record the tube number . If an additional kit is required at 
either of these visits, the subject’s information  will again be entered into ; however, 
 will now assign an additional kit containing tubes from the same treatment arm . The 
same process will be followed for the dispensing and recording of additional kit boxes and tubes. Each subject will maintain the same treatment assignment throughout the study.  
10.4.6  Compliance  
Subject s will be provided with a diary to record the date of Day 1, the time and date of dosing, any 
missed doses, other concomitant medications  and any AEs. Subject s taking fewer than  or more 
than  of the required doses over the 84 days  ± 4 days, or who missed scheduled applications 
for  consecutive days w ill be considered non-compliant with dosing, and excluded from the PP 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 34 of 67 
 
 population. Compliance with dosing will be verified by the use of the subject  diaries  and discussion 
with the subject. Compliance criteria are as outlined in the table below:  
Study Desig n Compliance Criteria  
 
 Treatment  
Duration Scheduled 
Doses   
  
 
 84 Days  84   
For subject s who are terminated from the study early, compliance will be determined from their 
duration in the study, up to the time they are considered early terminated. Subject s taking fewer 
than  of the required doses will be considered non-compliant with dosing. 
For example, if  a subject  is dropped from the study  after  days of enrollment and doses  times, 
then percent compliance is . 
10.5 Study Conduct  
10.5.1  Visit  1 (Day -14 to Day 1): Screening and Baseline Evaluation 
1. Informed Consent : Subject s who are willing to comply with study procedures will read, 
understand and sign the IRB -approved ICF . 
2. Medical History , Baseline Demographics  and Concomitant Medications : Review the 
subject ’s demographic s and medical history including concomitant medication use within the 
last 6 months. 
3. Pregnancy Test : A urine pregnancy test will be required of all female subject s of childbearing 
potential before  randomization. 
4. Vital Signs : Blood pressure, pulse, temperature and respiration rate will be recorded for each 
subject. In addition, height and weight will be measured to calculate total BSA . 
5. Application Site Reactions : A Medical  Investigator (MD, DO, CRNP or PA) will grade the 
individual signs and symptoms. This will serve as a baseline for subsequent assessments of 
application site reactions. See Appendix C. 
6. Dermatologic Assessment : A Medical Investigator  (MD, DO, CRNP or PA)  will i dentify and 
measure the target lesion (the most severe lesion at the Baseline visit)  and the location of t he 
treatment  area. The treatment area will be measured by a ssess ing % BSA affected . 
7. Investigator’s Global Assessment : A Medical Investigator  (MD, DO, CRNP or PA) will 
confirm the diagnosis of stable plaque psoriasis and perform a  severity rating according to the  
IGA to determine the severity of the plaque psoriasis i n the treatment area . See Appendix A. 
8. PASI Assessment : A Medical Investigator  (MD, DO, CRNP or PA) will perform the PASI  
Assessment on the target lesion site . See Appendix B. 
9. Inclusion/Exclusion  Criteria Review : Confirm the subject  meets all inclusion  criteria and 
none of the exclusion criteria.  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 35 of 67 
 
 10. Randomization : Eligible subjects selected for enrollment will be assigned a randomization 
number using . 
11. Dispense IP, Supplies , Subject Instructions  and Diary : Randomized subject s will be 
allocated a specific kit of IP via . The site will pull this specific kit for the subject 
and dispense  tubes, as needed. The site will also dispense study supplies (i.e., 
sunscreen) and a diary. The site will  instruct the subject  on the use of the IP, the completion of 
the diary and review the medications and/or treatments that are prohibited during the study. 
12. First Dose with IP : The site will instruct the subject on when the first dose of IP will be 
applied, which will be considered Day 1. The subject will record the date of Day 1 in their 
diary. 
 
 
 
 
For al
l other subjects, the first dose (Day 1) of IP will be applied on the evening of Visit 1. 
10.5.2  Vis
it 2 ( Day 28 ± 4 days ): Interim Visit  
1. Assess  Health Status : Review the subject ’s use of any new or ongoing concomitant medications 
and report any AEs . 
2. Pregnancy  Test: A urine pregnancy test will be required of all female subject s of childbearing 
potential.  
3. IGA : A Medical Investigator will perform a severity rating according to the IGA to determine 
the severity of the plaque psoriasis in the treatment area. See Ap pendix A. 
4. PASI Assessment : A Medical Investigator  will perform the PASI Assessment  on the target 
lesion site . See Appendix B. 
5. Application Site Reactions : A Medical Investigator  will evaluate any application s ite reactions 
since the last visit.  See Appendix C. 
6. Collect and Review Subject's Diary : Collect the diary from the subject and review for 
compliance with the protocol requirement s. If the diary is not returned, the staff will collect 
available information based on discussion with the subject.  
7. IP Collection, Assessment  and Dispensing (as needed) : Review the previously dispensed IP 
for usage. If a tube is empty, collect it from the subject. If a tube still contains significant product, redispense the tube to the subject. The subject should be dispensed enough IP to complete all 
required doses until Visit 3.  
 
 
8. Dispense  Supplies , Subject Instructions and Diary : Dispense the study supplies (i.e., 
sunscreen), as needed  and a new diary with Subject Instruction sheet . Re-review proper use of 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 36 of 67 
 
 the IP, the completion of the diary and the medications and/or treatments that are prohibited 
during the study. 
10.5.3  Visit 3: (Day 56 ± 4 days): Interim Visit  
1. Assess Health Status: Review the subject ’s use of any new or ongoing  concomitant medications 
and report any AEs . 
2. Pregnancy Test:  A urine pregnancy test will be required of all female subject s of childbearing 
potential.  
3. IGA : A Medical Investigator will perform a severity rating according to the IGA to determine 
the severity of the plaque psoriasis in the treatment area. See Appendix A.  
4. PASI Assessment : A Medical Investigator  will perform the PASI Assessment  of the Target 
Lesion Site . See Appendix B. 
5. Application Site Reactions : A Medical Investigator  will evaluate any application s ite reactions 
since the last visit . See Appendix C. 
6. Collect and Review Subject's Diary : Collect the diary from the subject and review for 
compliance with the protocol requirements . If the diary is not returned, the staff will collect 
available information based on discussion with the subject.  
7. IP Collection, Assessment  and Dispensing  (as needed ): Review the previously dispensed IP 
for usage. If a tube is empty, collect it from the subject. If a tube still contains significant product, 
redispense the tube to the subject. The subject should be dispensed enough IP to complete all 
required doses unti l Visit 4.  
 
 
8. Dispense Supplies , Subject Instructions  and Diary : Dispense the study supplies (i.e., 
sunscreen), as needed , and a new diary  with Subject Instruction sheet.  Re-review proper use of 
the IP, the completion of the diary and the medications and/ or treatments that are prohibited 
during the study. 
10.5.4  Visit 4: (Day 85 ± 4 days) End of Study Visit or Early Termination 
1. Assess Health Status : Review the subject ’s use of any new or ongoing concomitant medications 
and report any AEs . 
2. Pregnancy Test: A urine pregnancy test will be required of all female subject s of childbearing 
potential.  
3. Vital Signs : Blood pressure, pulse, temperature and respiration rate will be recorded for each 
subject . 
4. IGA : A Medical Investigator will perform a severity rating according t o the IGA to determine 
the severity of the plaque psoriasis in the treatment area. See Appendix A.  
5. PASI Assessment : A Medical Investigator  will perform the PASI Assessment  of the target 
lesion site . See Appendix B. 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 37 of 67 
 
 6. Application Site Reactions : A Medical Investigator  will evaluate any application s ite reactions 
(see Appendix C) since the last visit.  
7. Collect and Review Subject's Diary : Collect the diary from the subject and review for 
compliance with the protocol requirements. 
8. IP Collection : Collect all use d and unused tubes and return them to their corresponding kit 
box(s)  for storage. Record any lost or significantly damaged (i.e., punctured) IP. 
9. Discharge from Study : Discharge the subject from the study.  
10.6 Study Procedures  
10.6.1  Informed Consent  
At Visit 1, before performing any study- related procedures the study subject  must sign the IRB -
approved ICF. The ICF will be reviewed and approved by an I RB before study commencement.  
No subject  will be entered into the study without reading, understanding  and signing an ICF. If the 
ICF is required in any other language besides English, translation will be performed by a certified 
translator  and then approved by the IRB. 
10.6.2  Demographics 
At Visit 1, each subject  shall be required to provide basic demographic information: d ate of birth, 
gender, ethnicity and race.  
10.6.3  Medical History  
At Visit 1 subject s will be questioned about  their personal medical history , including psoriasis 
history . The medical history will include a complete review of all current diseases and their 
respect ive durations and treatments.  
10.6.4  Pregnancy Test  
All females of childbearing potential will have a urine pregnancy test performed at each visit. The 
test must be negative at Visit 1 for the subject  to be eligible for inclusion in the study. If a subject  
has to  wait for her menstrual period to start before applying the first dose of IP, the first dose of IP 
must be applied within 14 days of the negative Visit 1 pregnancy test. If the subject  is female and 
not considered of childbearing potential, then the reason must be documented in the subject ’s 
source document. 
Any subject who becomes pregnant during the study should be discontinued and Early Termination 
procedures (Visit 4  procedures ) completed. Pregnancy reporting procedures should be followed, as 
outlined i n section  10.7.6. The outcome of the pregnancy should be followed by the Investigator to 
the conclusion of the pregnancy (i.e., birth, termination or miscarriage). The pregnancy will be 
reported as an  AE from the time of first IP dose. 
10.6.5  Vital Signs 
The subject ’s vital signs will be recorded (blood pressure,  pulse,  temperature, and respiration rate) 
at Visits 1 and 4. At Visit 1, height and weight will also be measured to calculate BSA.  
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 38 of 67 
 
 10.6.6  Concomitant Medication  
At Visit 1, subject s will be questioned about current and  prior concomitant medication use  over the 
6 months  before  the Baseline visit. Subject s will also be questioned about ongoing or new 
concomitant medication use during the treatment period at Visits 2, 3 and 4.  The medications to be 
recorded will  include prescription and OTC medications and dietary supplements. 
At Visits 2 and 3 , any subject  who has used medications restricted by the protocol may be 
discontinued from the study . If discontinued, all Early Termination procedures (Visit 4 procedures) 
should be performed. 
10.6.7  Dermatologic Assessment  
At Visit 1 , the Medical Investigator  (MD, DO, CRNP or PA)  will assess the subject’s plaque 
psoriasis and calculate the %  BSA involvement using the subject’s hand (palm plus exten ded 
fingers) as an estimate of 1% BSA . For inclusion in the study , % BSA affected must be at least  2% 
but no more than 20%. The Investigator will then  identify and measure the size of the treatment 
area and identify the most severe psoriasis lesion within the treatment area . This lesion will be 
designated  as the target lesion . 
10.6.8  IGA 
At Visit 1, a Medical  Investigator  (MD, DO, CRNP or PA) should document a confirmed diagnosis  
of stable plaque psoriasis. 
At each visit, a Medical  Investigator  will perform a  psoriasis severity rating according to the  IGA 
(see Appendix A) . At Visit 1 , the IGA must be a score of  3, 4 or 5 for the subject  to be eligible for 
inclusion. At Visit 4 (or Early Termination), the IGA score will be used to determine Treatment 
Success or  Treatment Failure for the primary endpoint , with treatment success defined as none, 
minimal  or mild disease, a score of 0, 1 or 2 within the treatment area. Further, at Visit 4 (or E arly 
Termination), the IGA score will be used to evaluate the secondary endpoint, which is the 
proportion of subjects with disease severity consistent with none or minimal , a score of 0 or 1, 
within the treatment area.  
 
The IGA is a static scale and no reference to previous scores for the subject  should be made during 
this assessment.  
10.6.9  PASI  
At Visit 1 , a Medical Investigator  (MD, DO, CRNP or PA) will identify the most severe lesion, and 
this will be designated the target lesion . 
At each visit , a Medical Investigator will perform the P ASI at the target lesion site according to the 
PASI scale (see Appendix B ). At Visit 1 , the PASI  score for plaque elevation at the target lesion  
must be  a 3, 4 or 5 for the subject  to be eligible for inclusion. At Visit 4 (or Early Termination), the 
PASI  score will be used to  evaluate the secondary endpoint , which is  the proportion of subjects 
with target site plaque elevation, scaling  and erythema scores of less than or equal to 1. 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 39 of 67 
 
 10.6.10  Application Site Reactions 
At Visit 1, the Investigator will grade the individual signs and symptoms per Appendix C. This will 
serve as a baseline for subsequent assessments of application site reactions. At Visits 2, 3 and 4, 
the Investigator will evalua te the subject  for local application s ite reactions ( erythema, dryness, 
burning /stinging, erosion, edema, pain, and itching) based on the scale provided in Appendix C . 
Reactions will be documented in source documents for each subject . 
10.6.11  Inclusion and Exclusi on Criteria Review  
At Visit 1, the site will confirm that the subject meets all inclusion criteria and none of the 
exclusion criteria.  If the subject does, they are eligible for enrollment in the study and will be 
randomized to a treatment group. If the subject does not, their participation will be complete and 
they will be discontinued as a screen failure.  
10.6.12  Randomization 
At Visit 1, elig ible subjects selected for enrollment will be assigned a randomization number 
using . The system will allocate a kit box of IP to the subject in a double-blind fashion. 
The kit box will contain  of product for a single treatment arm (Test, Reference or 
Placebo). 
10.6.13  Dispensing  IP 
An  will dispense  an initial supply of  IP at Visit  1, and will resupply the 
subject at Visit  2 and /or 3 or an Unscheduled  Visit, as needed.  The amount of IP dispensed is at the 
discretion of the Investigator based on the amount of BSA affected with psoriasis. After the initial 
 of IP have been dispensed  and fully used  and/or the tube has become lost or significantly 
damaged (i.e. , became punctured), an additional kit box(s) of the same treatment group may be 
allocated to the subject using .  
 
 
 
 
will ensure th at all Drug Dispensing Logs are completed co rrectly.  Any 
dispensing task conducted by the , will be verified by a second person using 
the . 
10.6.14  Returning  IP 
At Visit 2 and/or 3, an  will review the previously dispensed  IP. If a tube is 
empty, it will be collected  from the subject. If a tube still contains significant product, the tube will 
be re-dispensed to the subject. At Visit 4, all used and unused tubes will be collected. The 
 will ensure that all Drug Dispensing Logs are completed correctly. Any 
collection task conducted by the , will be verified by a second person using 
the  
Any lost IP will be recorded  in the drug dispensing log and the Comments  section of the source 
document. 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 40 of 67 
 
 Any observed tube unblinding will be recorded in the Comments section of the source document 
and reported to the CRO and sponsor immediately.  
10.6.15  Subject Dosing  Instructions and Diary  
Subjects will be instructed to use the IP as described in section 10.4.1. 
The site will instruct the subject on when the first dose of IP will be applied, which will be 
considered Day 1. T he subject will record the date of Day 1 in their diary.  
 
 
 
 
For a
ll other subjects, the first dose (Day 1) of IP will be applied on the evening of Visit 1. 
Subje
cts will be provided with a diary at Visits 1, 2 and 3. Subject s will be asked  to record the date 
of Day 1 , the time  and date of each dose, any missed doses,  any AEs that have occurred  and any 
concomitant medications utilized  throughout the study. The site will review the diary and evaluate 
the subject’s compliance with the protocol at Visits 2, 3 and 4, based on any new additions to their 
medical history, new or changed concomitant medications, AEs and dosing compliance. If the diary 
is not returned, the staff will collect available information based on discussion with the subject. 
The subject will also be reminded of the medications and/or treatments that are prohibited during the study. 
If the subject is no longer eligible for participation at Visit 2 and/or 3, the site will conduct Early 
Termination (Visit 4) procedures. 
10.6.16  Standardized Sunscreen  
Along with the IP at Visit 1 , the subject  will be provided with standardized sunscreen  (Neutrogena 
Ultra Sheer or similar) for use when needed. The use of the sunscreen should be documented on 
the concomitant medication page on the source documents and eCRFs . If additional sunscreen is 
needed during the study, additional sunscreen can be dispensed at Visit 2 and/or Visit 3 or an 
Unscheduled V isit. 
10.6.17  Health Status/AEs  
At Visits 2, 3 and 4 subject s will be questioned regarding any changes in their medical status s ince 
their previous visit. Any significant health changes observed after signing of the ICF into the study 
will be reported as AEs, as deemed appropriate by the Investigator . 
10.7 AEs/SAEs 
The subjects will be monitored throughout the study for any  AEs. AEs wil l be collected through both 
solicited and unsolicited means and subsequently coded in tabular form using the MedDRA
® (Version 
18.1 or higher) Adverse Event  Dictionary. The subjects will be requested  to report signs, symptoms  
and any changes in health to the clinic staff. Observed changes during the dermatology exam and/or 
clinical assessment at each visit (i.e., changes in the application site reaction) should be assessed by the 
Investigator  to determine (in their opinion) if the change  should be reported a s an AE or not. Severity 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 41 of 67 
 
 of each AE will be determined by the staff based on observation and questioning of the subjects. The 
Investigator  will judge the relationship of the event to the study treatments.  
10.7.1  Definitions  
An Adverse Event / Experience is any untoward medical occurrence in a subject administered a 
pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laborato ry finding, for example), symptom  or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product. 
An SAE  is any untoward medical occurrence that at any dose:  
• results in death  
• is life -threate ning 
• requires inpatient hospitalization or prolongation of existing inpatient hospitalization 
• results in persistent or significant disability / incapacity  
• is a congenital anomaly / birth defect  
• is medically significant: Medical and scientific judgment shou ld be exercised in deciding 
whether expedited reporting is appropriate in other situations, such as important medical 
events that may not be immediately life -threatening or result in death or hospitalization but 
may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above. These should also usually be considered serious.  
These characteristics/consequences have to be considered at the time of the event. For example, regarding a life- threatening event, this refers to an event in which the subject was at risk of death 
at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.  
An Adverse Drug Reaction (ADR)  is any AE for which the Investigator  or sponso r assess a 
reasonable possibility for a causal relationship to a medicinal product, s ee 10.7.3 below. 
An Unexpected Adverse Reactions is defined as an ADR,  the nature or severity of which is not 
consistent with the Reference Safety Information (Appendix D ). The term ‘severity’ is used here 
to describe the intensity of a specific event. This has to be distinguished from the term ‘serious’. Reports which add significant information on the specificity, increase of occurrence or severity of 
a known, already doc umented serious adverse reaction constitute unexpected events.  
Information about common side effects already known about the IP can be found in the Reference Safety Information ( Appendix D ) or will be communicated in the form of Investigator  
Notifications.  These common side effects are also listed in the informed consent . The common side 
effects will be discussed with the subject  prior to their signing of the informed consent. 
For further details, please refer to the “Quick Reference Guide for Completing th e SAE Form”  for 
completing the “Serious Adverse Event Report Form” (Novartis form). 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 42 of 67 
 
 10.7.2  Severity of A Es 
The term ‘severity’ is used here to describe the intensity of a specific event. This has to be 
distinguished from the term ‘serious’. In the course of the study, the Investigator  will determine 
whether any AE ’s have occurred and will grade their severity as follows:  
Mild:  Transient or mild discomfort (<  48 hours); no medical intervention/therapy 
required  
Moderate:  Mild to moderate limitation in activity - some assistance may be needed; no 
or minimal medical intervention/therapy required  
Severe:  Marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospitalization possible  
10.7.3  Relationship to the IP 
The Investigator  should evaluate all AEs considering all accessible data, at any time new 
information becomes available. The definition of IP includes the Test product under evaluation and 
the Reference product or Placebo  that is given during any phase of the study. 
The Investigator  should assess whether or not, in his/her expert opinion, the AE is suspected to the 
drug according to the following considerations: 
Suspected:  The temporal relationship of the clinical event to study treatment 
administration makes a  causal relationship possible , and other 
drugs, therapeutic interventions or underlying conditions do not provide a sufficient explanation for the observed event. 
Not suspected:  The temporal relationship of the clinical event to study treatment 
administration makes a causal relationship unlikely , or other drugs, 
therapeutic interventions or underlying conditions provide a sufficient 
explanation for the observed event. 
Causality assessments are critical and must be provided for each unique AE in relation t o each IP. 
Missing causality assessments will be handled as suspected to IP by the sponsor.  
10.7.4  AE Documentation 
Any AE (non- serious and serious) occurring after the subject has provided study- specific informed 
consent, and until the last study visit of the su bject, has to be recorded on the AE pages of the eCRF.  
The occurrence of AEs should be sought by non- directive questioning of the subject at each visit 
during the study. AEs also may be identified when they are volunteered by the subject during or between visits or during physical examination, laboratory test or other assessments. All AEs should 
be given appropriate medical care. Treatment may include one or more of the following: no action 
taken (i.e. , further observation only); IP dosage adjusted/temporar ily interrupted; IP permanently 
discontinued due to this AE; concomitant medication given; non- drug therapy given, subject  
hospitalized / subject ’s hospitalization prolonged. The treatment of the AE should be documented 
in the eCRF. In addition, the action taken with the IP should be documented, and should be assigned 
to one of the following categories: not changed, withdrawn, reduced, increased, interrupted, 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 43 of 67 
 
 unknown and not applicable. Concomitant medication, other treatments or changes in the 
administration of the IP should be specified and documented. 
Medical conditions/diseases present before starting IP are only considered AEs if they worsen after 
enrol lment. Abnormal laboratory values or test results constitute AEs only if they induce clinical 
signs or symptoms, are considered clinically significant  or require therapy.  
Once an AE is identified, the Investigator  should follow -up as specified below. Each time, the 
outcome should be documented and assigned to one of the following categories: not 
recovered/ unchanged, condition deteriorating, recovered/resolved, improving/recovering, 
recovered/resolved with sequelae, fatal or unknown. The assessment of an AE should be made at each planned visit (or more frequently, if necessary). The Investigator  should document in the 
eCRF any changes in seriousness, severity, the suspected relationship with the IP, the interventions 
required to treat it, and the outcome. 
AEs occurring between informed consent and first dosing 
Any AE occurring between study- specific informed consent and first dosing will be documented 
as “screening event”, with a IP causality assessment “IP not yet administered”. 
AEs occurring after first dosing  
The Investigator  should follow all AEs which occurred from first dosing and during the course of 
the study to the last visit of the subject  until the AE has resolved or stabilized or the subject has 
been lost to follow -up. 
Ongoing SAEs  at the time of last visit  
For any SA Es still ongoing at the time of last visit, the Investigator  should continue to follow -up 
until the SAE has resolved or has stabilized / is judged permanent , for SAEs considered to be related 
to IP ( serious adverse drug reaction [ SADR ]), and for up to 30 days after the last visit of subject 
for non- related SAEs. The Investigator  should send SAE follow -up reports to recipients as per the 
‘SAE Reporting’ section 10.7.5 below. 
SAEs occurring after the last visit  
At the last visit, the Investigator  should instr uct each subject to report any new SAE  (beyond the 
protocol observa tion period) that the subject, believes might reasonably be related to study 
treatment. The Investigator  must report the SADR to recipients as per the ‘SAE Reporting’ section 
10.7.5 below. 
10.7.5  SAE Reporting  
It is vitally important that the Investigator reports immediately , (i.e., no later than 24 hours 
after awareness) , any SAEs  or updates to previously reported SAEs, even if the Investigator  does 
not consider the AE  to be drug -related.  
The Investigator  should send SAE reports on the “Serious Adverse Event Report Form” (Novartis 
form), as initial or follow -up reports, via fax or email to the Local Person for Pharmacovigil ence 
(LPPV ) (listed below), and in copy to the responsible Medical Monito r/CRO Contact  and the 
sponsor (listed below) , to the email addresses provided in the table below. 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 44 of 67 
 
 The Investigator  should also send all updates / new information on a new SAE Report Form as a 
follow-up to the previously reported SAE. The follow-up information should describe whether the 
event has resolved or continues, if a diagnosis is available, if and how it was treated, and whether the subject continued or withdrew from study participation. 
Recurrent episodes, complications or progression of the initial  SAE must be reported as follow-up 
to the original episode, regardless of when the event occurs.  
Any new SAE (that is considered completely independent of a previously reported SAE) should be 
reported as a new and separate initial SAE report.  
Any queries from the LPPV, CRO or sponsor  regarding SAE reports should be answered by the 
Investigator  within 24 hours. 
For more detailed information refer to the “Quick Reference Guide for Completing the SAE Form”.  
The Investigator  should retain a delivery notification for all recipients in the Investigator  study file.  
 
 
 
    
 
Addresses for SAE and other Safety Reporting  
LPPV, Sandoz (United S tates ) 
Name :  
 
Email:  
Fa
x:  
CRO Contacts  
 
Cell P
hone:  
Phone:  
Fax:  
Email:   
 
Phone:  
Fa
x:  
Email:  
Sponsor Contacts 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 45 of 67 
 
  
 
Phone:  
Fa
x:  
Email:   
 
 
Phone:  
Fa
x:  
Email:  
 
The responsible contact persons for questions are:  
 
 
Phone:  
Fa
x:  
email:   
 
Phone:  
eF
ax:  
email:  
 
Investigator Notification 
If an ADR is not listed in the Reference Safety Information (e.g., Package Insert ), the sponsor may 
urgently require further information from the Investigator  for Health Authority reporting.  
The sponsor may, if applicable, issue Investigator  Notifications of unlisted SADRs ( Suspected 
Unexpected S erious Adverse Reaction s [SUSARs] ) to all Investigator s concerned with any study 
with the same IP.  
The submission of these Investigator Notifications, if applicable, to IRBs is the responsibility of 
the Investigator or the CRO as stipulated in the study contract.  
Health Authority Reporting 
The sponsor will submit all reportable cases within the requested timelines to all concerned authorities.  
Under 21 CFR 320.31(d)(3), the sponsor  or CRO must inform other Investigator s involved in the 
study plus the FDA within 15 days of  becoming aware of the occurrence of the SAEs. When a 
serious AE is death, s ponsor or CRO must inform other Investigator s involved in the study plus the 
FDA within 7 days of becoming aware of the event . SAEs that occur with the Test, Reference or 
Placebo product must be reported. 
IRB Reporting  
AEs that are evaluated by the Investigator  as "Serious" should be reported by the Investigator  to 
the sponsor and CRO  within 24 hours, and the IRB as soon as is practically possible, preferably 
within 24 hours, whethe r or not they are considered expected or drug -related.  
Investigator Safety Reporting Training  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 46 of 67 
 
 The Principal Investigator  will be  trained on the sponsor SAE/AE and pregnancy reporting 
obligations as defined in the study protocol. Training will be documented. 
10.7.6  Pregnancies 
Tazarotene may cause fetal harm when administered to a pregnant woman by potentially inducing 
teratogenic and developmental effect associated with retinoids. Compliance with adequate birth 
control measures described in this protocol , including a negative pregnancy test before dosing and 
its commencement during a normal menstrual period, is of paramount importance. The Investigator  
must report any cases of pregnancy of subjects in the course of a study immediately (within 24 
hours) of  awareness to the LPPV and with copy to the responsible Medical Monitor/CRO Contact 
and the sponsor , to the email addresses provided in the table above , as described in section 10.7.5. 
 
 
The Investigator  should immediately withdraw the subject from the study, and should follow -up 
each case of pregnancy  through the expected deliv ery date, and report the outcome, including 
spontaneous or voluntary termination, details of the birth and any birth defects, congenital 
abnormalities, or maternal and/or newborn complications. 
  
 
 
 
10.7.7  Quality  Complaints  
In case of quality complaints (technical or transport complaints), the Investigator  within 24 hours 
of learning of its occurrence informs the Medical Monitor/CRO Contact and the sponsor via the 
email addresses provided in the table above in section 10.7.5. Reporting should include all details 
relevant to the quality complaint. The monitor /CRO Contact and/or sponsor  may reach out to the 
site for further detail. Any queries from the CRO or sponsor regarding quality complaints  should 
be answered by the Investi gator  within 24 hours. The Investigator  should document the quality 
complaint in the subject's source document (for subject's specific quality complaints) and/or the 
Investigator 's study file (for site specific quality complaints) , as applicable.  
Any AE associated with a quality complaint needs to be documented and reported in addition by 
the Investigator  as described in section 10.7.4 and 10.7.5. 
 
 
 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 47 of 67 
 
 10.7.9  Reconciliation 
Reconciliation between the safety database of the sponsor and the clinical database at the CRO will 
be done periodically  and at the end of the study  by comparing line listings from the safety database 
with the data in the clinical database.  
The e CRFs / the clinical database will be reviewed  for potentially unreported cases. For any 
reportable case, the following parameters need to match exactly between the clinical and the safety 
database: trial number, site number, subject  identification  num ber, investigational drug, 
seriousness, date of death (if applicable) and Investigator  causality. All other parameters only need 
to be plausibly and medically consistent. For any SAE  assessed as suspected, a more detailed 
reconciliation should be conducted, including also treatment dates and medical history. 
11.0 STATISTICAL METHODS  
11.1 Statistical Plan  
A Statistical Analysis Plan (SAP), including study data report format, detailing the intended statistical 
analysis of the study data, will be prepared as a separate document and finalized before database lock. Any deviation from the original statistical plan will be described and justified in the final report, as appropriate. The procedure for accounting for missing, unused and spurious data will be included in 
the SAP. 
If not otherwise specified, statistical significance is defined as p < 0.05, two-sided . Data  will be 
summarized with respect to demographic and baseline characteristics, efficacy variables and safety 
variables.   
 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 48 of 67 
 
 All statistical analysis will be co nducted using SAS®, Version 9.4 or higher.  Datasets will be prepared 
using headings from Clinical Data Interchange Consortium (CDISC) , Study Data Tabulation Model  
(SDTM) implementation for human clinical trials , and Analysis Dataset Model  (ADaM ). 
11.2 Sample Size Determination  
Sample size calculations were performed using  For the primary endpoint 
analysis, the rate of treatment success for the Reference treatment after 12 weeks of treatment is 
expected to be approximately  in the PP population. Assuming that the rate s of treatment success 
for Test and Reference  treatment s are the same, a sample size of  subjects in each active group in 
the PP population will provide approximately  power to demonstrate therapeutic equi valence (i.e., 
the 90% confidence interval (Yates’ continuity -corrected) of the absolute difference between the Test 
and Reference rates of treatment success is within a defined equivalence range [ -20% to + 20%]).  
The rates of treatment success for the Placebo and active treatment groups after 12 weeks of treatment 
are assumed to be approximately  and at least  respectively, in the mITT population. Using a 
1:1 (active: placebo) randomization scheme, and assuming the conversion rate from mITT  to PP 
population will be about  subjects in each treatment group (Test, Reference and Placebo) of 
the mITT population will provide at least  power to demonstrate superiority of active over Placebo 
at the 5% significance level ( p < 0.05, two-sided continuity -corrected Z -Tests and a pooled response 
rate for the standard error of the difference in proportions) . 
Under the above assumptions, the overall study power to demonstrate therapeutic equivalence and superiority is estimated to be at least  To allow for approximately  of subjects who may drop 
out from the study or are otherwise non- evaluable, up to 855 subjects may be randomized to obtain  
subjects in the mITT population (i.e.,  per treatment arm).  
11.3 Study Populations  
11.3.1  PP Population  
The PP population will include subject s that compl y with the protocol as follows:  
• All randomized subject s who me et all inclusion and exclusion criteria.  
• Make the final study visit  (Visit 4)  within the protocol window of Day 85 ± 4 days with no 
PDs that would affect the integrity of the data . 
• Comply with study restrictions including concomitant medications.  
• Apply the IP appropriately and are within  compliant with dosing during the 12 
weeks (Day 8 5 ± 4) of treatment. 
• Do not miss the scheduled applications for more than  
 
 
 
 
 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 49 of 67 
 
  
 
 
11.3.2  Mod
ified  Intent -to-Treat (mITT) Population  
The mITT population will include all subject s in the PP population plus all randomized subject s 
who meet all inclusion/exclusion criteria, apply at least one dose of assigned product, and return 
for at least  one post -Baseline evaluation.  
        
 
11.3.3  Safety Populations  
All subject s who a re randomized and received  the IP will be included in the  analysis of safety.  
11.4 Baseline Comparability 
Baseline characteristics will be evaluated  separately for the PP, mITT and S afety populations.  
The following baseline demographics  and parameters (determined from their initial study vis it) will be 
evaluated : 
o Age at the time of consent/assent  (years)  
o Gender (Male/Female)  
o Ethnicity (Hispanic/non- Hispanic) , Race (White, Black/African American, Native 
Hawaiian or Other Pacific Islander, Asian, American Indian or Alaska Native, Other)  
o Baseline total BSA affected with Psoriasis  
o Baseline percent BSA affected with Psoriasis  
o Baseline PASI Score and B aseline S cores for Individual Components (Erythema, S caling  
and Plaque Elevation) 
o Baseline IGA Score 
o Treatment location  
o Treatment area size (area)  
o Target lesion s ize (area)  
Summary tables by treatment group will be presented. Continuous variables will be summarized using 
descriptive statistics (number of observations, median, minimum, maximum, mean and SD). 
Categorical variables will be summarized using frequencies and percentage. Baseline treatment 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 50 of 67 
 
 comparisons will be presented using Chi -Square or Cochran -Mantel -Haenszel tests for the categorical 
variables, and analysis of variance (ANOVA) for the continuous variables. 
All data will be  listed by treatment and s ubject . 
11.5 Efficacy Endpoints  
Primary Efficacy Endpoint  
Proportion of subject s with treatment success (defined as none, minimal  or mild disease, a score of 0,  
1 or 2 within the treatment area ) on the IGA at the Week 12 visit ( Day 85 ± 4 days, End of Study). 
Secondary Efficacy Endpoint s 
1. Proportion of subject s with disease severity at the Week 12 visit (Day 85 ± 4 days, End of 
Study) consistent with none or minimal , a score of 0 or 1, within the treatment area on the IGA, 
AND  
2. Proportion of subjects with target site plaque elevation, scaling  and erythema scores of less 
than or equal to 1 on the PASI at the Week 12 visit (Day 85 ± 4, End of Study).  
11.6 Primary and Secondary Endpoint  Analys es 
Therapeutic Equivalence Analysis  
Therapeutic equivalence will be evaluated for both primary and secondary endpoints using the PP 
population, with results in the mITT population being supportive. For the dichotomized primary endpoint (proportion of treatment success), if the 90% confidence  interval (with Yates’ Correction 
Factor) of the difference between the proportion of subjects considered a “treatment success” in the 
Test and the Reference treatment groups at Week 12  is contained within the pre -defined equivalence 
limits [ -20%, +20%], then therapeutic equivalence will be considered to have been supported for the 
endpoint. The same statistical approach will be conducted for  analysis of  the two dichotomized 
secondary endpoints in the PP and mITT populations. 
To declare therapeutic equivalence of the Test product to the Reference product, therapeutic 
equivalence must be demonstrated for only the primary endpoint in the PP population. 
Superiority to Placebo Analysis 
The primary measure of superiority will be evaluated using the mITT  population and LOCF  for missing 
efficacy values. The results in the PP population will be considered supportive. The superiority of the Test and Reference products over Placebo will be concluded for the primary endpoint if the proportion 
of treatment success at Week 12 is statistically superior to Placebo ( p < 0.05, two- sided  a Cochran-
Mantel -Haenszel  exact test stratified by clinical site ) using the mITT population and L OCF . The same 
statistical approach will be conducted for analysis of  the two dichotomized secondary endpoints in the 
mITT and PP populations. 
To declare superiority of the Test and Reference products over Placebo, their superiority must be 
demonstrated for only the primary endpoint in the mITT population. 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 51 of 67 
 
 11.7 Treatment- by-Site Interaction and P ooling of Clinical Sites  
As this is a multiple -site study, the interaction of treatment -by-site may be evaluated by the Cochran-
Mantel -Haenszel test (stratified by site) at the 5% significance level (p  < 0.05, 2-sided) for the primary 
efficacy endpoint in both the PP population (for equivalence testing) and mITT population (for 
superiority testing).  
   
 
 This will include examination of responder rates at each site where 
sample sizes per treatment may be influen tial in the ass essment of the interaction.  
11.8 Safety Analysis  
AEs will be classified using standard MedDRA terminology Version 18.1 or higher and  summarized 
by treatment group. Summary tables comparing the type, date of onset, date of resolution, incidence, 
severity , relati onship to the IP, outcome and action taken will be prepared by treatment group. Should 
sufficient data exist, AE frequencies will be compared among treatments using Fisher’s exact test or a 
similar test.  
Application site reactions (erythema , dryness, burning /stinging, e rosion, e dema , pain , itching ) recorded 
at each visit will be  compared among treatment groups. A descriptive analysis comparing the 
application site reactions for each treatment group will be created . 
Concomitant medication use during the treatment period will be tabulated by subject. 
Signs and symptoms of psoriasis  will not be considered  AEs , unless in the Investigator ’s opinion, they 
have increased in frequency and/or severity to such an extent that the Investigator /subject  considers 
that it is in the subject ’s best interest to be dropped from continued participation in the study and given 
alternative therapy for their condition. 
All randomized subjects who received IP will be included in the comparative safety analysis . 
12.0 REGULATORY OBLIGATIONS  
12.1 Institutional  Review Board  
The study protocol, ICF, subject handouts, if required, and any specific advertising will be submitted 
to, and approved by, an I RB in writing  before the start of the study , as defined by FDA regulations . A 
form must b e issued  by the IRB noting the approvals . Based on the IRB’s internal policy, the form may 
be signed by the IRB chairman or designee . The Reference product package insert  will also be 
submitted for the IRB’s review. The notification of the board's approval  along with a description by 
profession and gender of the board's composition will be provided to the sponsor. 
Any changes to the protocol, as well as a change of Investigator , which is approved by the 
sponsor/CRO, must also be approved by the IRB (s) and d ocumentation of this approval provided to the 
sponsor or designee. Records of the IRB review and approval of all documents pertaining to this study must be kept on file by the Investigator  and are subject to inspection by regulatory authorities during 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 52 of 67 
 
 or after completion of the study. SAEs must also be reported to the IRB  per their policy; however, the 
Investigator /CRO  is encouraged to report all SAEs to the IRB as soon as practically possible, preferably 
within 24 hours, even if the IRB’s reporting require ment is longer . 
Periodic status reports must be submitted to the IRB  per their policy, but  at least annually, as well as 
notification of study completion or termination with a final report within one (1) month after close out . 
A copy of all reports submitted to the IRB must be sent to the sponsor. 
The Investigator  will ensure that an IRB that complies with the requirements set forth in Part 56 (Title 
21 Code of Federal Regulations) will be responsible for the initial and continuing review and approva l 
of the proposed clinical study. 12.2 Subject Confidentiality  
All applicable Investigator s and study staff must comply with the federal medical Privacy Rule 
authorized by the HIPAA ), which requires most health care providers to take new measures to protect 
the privacy of individually identifiable health information. The Privacy Rule’s requirements extend to 
identifiable health information used or disclosed in research. The HIPAA Privacy Rule reinforces 
clinical Investigator s’ existing obligations to protect the  privacy of identifiable health information under 
state law, codes of medical ethics and the federal regulations governing research. 
Also, in compliance with federal guidelines regarding the monitoring of clinical studies and in 
fulfillment of his/her obli gations to the sponsor, it is required that the Investigator  permit the study 
monitor, sponsor auditor, and/or FDA representative to review that portion of the subject’s medical 
record that is directly related to the study. This shall include all study rel evant documentation including 
subject medical histories to verify eligibility, admission/discharge summaries for hospital stays 
occurring while the subject is enrolled in the study and autopsy reports for deaths occurring during the study. 
As part of the r equired content of informed consent, the subjects must be informed that his/her medical 
chart may be reviewed by the sponsor, the sponsor’s authorized representatives or FDA. Should access 
to the medical record require a separate waiver or authorization, it is the Investigator’s  responsibility to 
obtain such permission from the subject in writing before the subject is entered into the study. 12.3 Study  Documentation 
This study will be conducted in compliance with the protocol ; Good Clinical Practices (GCP) and a ll 
applicable regulations, including the Federal Food, Drug and Cosmetics Act, US applicable Code of 
Federal Regulations (title 21), parts 50, 56, 312, 320 , and any IRB requirements relative to clinical 
studies ; and the Declaration of Helsinki, June 1964, as modified by the 64
th World Medical Association 
General Assembly, October 2013.8,17-19 The Investigator  will permit trial- related monitoring, audits, 
IRB review and regulatory inspections providing direct access to source data/documents.  
12.3.1  Protocol 
The Investigator  indicated on Form FDA 1572 will act as the Principal Investigator at his/her 
respective study site. Protocols will be noted as approved by placement of the signatures of the 
sponsor and   Representatives on the signature page.  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 53 of 67 
 
 12.3.2  Informed Consent  
An ICF that includes all of the relevant elements currently required by FDA and local state 
regulations will be provided to each prospective study subject  before being screened into the study. 
The type and method of study, tests to be administered, any potential or possible hazards, and the 
subject ’s right to withdraw from the study at any time will be explained to the subject s by the 
Investigator  or designee. Once the Investigator  or designee is assured that an individual candidate 
understands the implications of participating in this study, the subject  will be asked to give consent 
by signing and dating in the appropriate areas of the ICF. The Investigator  or designee will also 
sign and date the form, along with a staff member who will sign the ICF as a witness to verify that the subject  has indeed received information. If any other language is required, translation will be 
performed by a certified translat or and will be IRB-approved. A copy of the ICF will be provided 
to the subject . A notation will be made in the subject’s medical record indicating the date informed 
consent was obtained.  
12.3.3  Protocol and Informed Consent Changes  
The procedures defined in the protocol will be carefully reviewed to ensure that all parties involved with the study fully understand the protocol. Sponsor approved changes to the protocol or the I CF 
will be implemented as revisions to the original documen ts and will require additional review and 
approval by the IRB. Revisions to the original protocol will be documented in amendments, incorporated as a preface to the new version. Any revision that substantially alters the study design 
or increases potential  risk to the subject  requires the subject ’s consent to continue in the study. The 
approvals will be processed in accordance with the established IRB procedures. Copies of all 
protocol and ICF amendments/revisions, along with letters noting IRB approval, wi ll be submitted 
to the sponsor. 
The only circumstance in which a  protocol amendment may be initiated without prior IRB approval 
is to eliminate apparent immediate hazards to a subject or subjects. However, the Investigator  must 
notify the IRB immediately, no later than within five (5) working days after implementation.  
12.3.4  Source Documents and Case Report Forms  
All subject s will be identified by initials  and date of birth . Randomized subjects will also have a 
unique subject  randomization number. Source document s will be used to record all study -related 
data. Source document entries will be used to complete eCRFs  which will record all critical study 
information . A set of eCRFs  will be completed for each subject  enrolled in the study. All data from  
eCRFs will be r eviewed, evaluated and signed by the Investigator , as required.  All eCRFs will be 
cross referenced to source documentation by the study monitor and/or the sponsor to ensure 
accurate transcription of the data.  
The original source documents and a copy of the corresponding eCRFs (electronic or print out) will 
be retained by the Investigator. Subject s who terminate early from the study will have the Visit 4 
(End of Study /Early Termination ) Source/eCRF completed. 
Primary Source Documents  
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 54 of 67 
 
 The Investigator  must maintain source documents supporting significant data for each screened 
subject’s medical notes. Standardized source document forms will be utilized for this study and 
will include original records . 
During monit oring visits the monitor will validate data in the eCRFs against the sources of data.  
If a subject does not qualify for enrollment, they will be considered a screen failure. The reason for 
their disqualification will be included in their source document and summarized in the CSR. 
Case Report Forms  
Source document entries will be used to complete eCRFs for enrolled subjects. All data and eCRFs 
will be reviewed, evaluated and signed by the Investigator , as required.  Further details will be 
provided in the dat a management plan.  
Supporting Documentation The Investigator  site file will be maintained by the Investigator  and study staff and will be available 
for review during monitoring, auditing and regulatory agency inspections, if applicable . 
Details will be provided in the monitoring plan. 
12.3.5  Drug Accountability  
All IP receipt, inventory, selection of retention, dispensing, dosing and reconciliation records will 
be maintained in compliance with federal regulations. The IP will be dispensed to qualified study 
subjects according to established procedures. Drug accountability will be maintained by the site 
throughout the study, and will be reviewed by the monitor throughout the study. At the end of the 
study (i.e., at the Site’s C lose Out visit) all used and unused IP, with the exception of required 
retention samples,  will have a documented inventory conducted and will be returned to sponsor or 
designee.  
12.3.6  Drug Storage 
All IP will be stored at 20°C to 25°C ( 68°F to 77 ºF), with excursions permitted from -5°C  to 30°C 
(23ºF to 86 ºF). IP should be stored in a secure place with limited access by authorized individuals 
only. The Investigator  will be responsible for maintaining accurate records of IP receipt, retention, 
dispensing and return.  
12.3.7  Retention of Reserve Samples  
For e very IP shipment received at the Investigator  site, the Investigator  (or designee) will randomly 
select one block of IP for retention. As per the Code of Federal Regulations Part 21, Section 
320.38(e), “Each reserve sample shall be stored under conditions consistent with the product 
labeling and in an area segregated from the area where testing is conducted and with access limited 
to authorized personnel. Each reserve sample shall be retained for a period of at least 5 years 
following the date on which the application or supplemental application is approved, or, if such 
application or supplemental application is not approved, at least 5 years following the date of completion of the bioavailability study in which the sample from which the reserve sample was obtained was used.” 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 55 of 67 
 
 Instructions on how to select retention samples will be supplied to the Investigator  in writing with 
each shipment, along with a shipment/retention acknowledgment form that must be completed by 
the study staff and signed by the Investigator . The selection process will ensure a sufficient amount 
of retention samples are retained as per sponsor requirement.  
The number of each kit  
box in the  block selected  for retention will be noted on the drug accountability form as a retention 
sample, in addition to the retention sample log  and sponsor supplied acknowledgment . These blocks 
will be affixed with a label provided by  to be cle arly marked as retention samples and are 
not to be used for dispensing to study subjects . Retention samples should not be returned to the 
sponsor at any time. At the completion of the retention period, the Investigator  must contact the 
sponsor if they wish  to destroy the retention samples. If destruction is authorized, the sponsor must 
supply this directive to the Investigator  in writing.  
12.3.8  Return of Clinical Supplies  
Once authorized by the sponsor, with the exception of the retention samples, all used and unused 
kits of IP will be inventoried and returned to , who will store the IP until 
sponsor authorized destruction: 
 
 
 
12.3.9  Pre
gnanc y and Breastfeeding  
Tazarotene cream is designated as Pregnancy Category X; therefore there is a potential risk of 
teratogenicity. Therefore, all females of childbearing potential should be maintained on an appropriate method of contraception throughout the study to prevent pregnancy. Females that are 
lactating, breastfeeding or trying to become pregnant should not be enrolled in the study. The ICF 
will clearly outline the risk and this requirement.  
All females of childbearing potential will have a pregnancy test performed at each clinic visit. The 
pregnancy test will have a minimum sensitivity of at least 50 mIU/ml for hCG. The results of all 
pregnancy tests (positive or negative) will be documented. A negative urine pregnancy result must  
be obtained at screening (Visit 1)  before  study participation. Subjects with a positive pregnancy 
result during screening will not be enrolled in the study. Before study enrollment, females of 
child bearing potential must be advised of the importance of avoiding pregnancy during study 
participation. 
 
Childbearing Potential Defined as: Non-Childbearing Potential Defined as:  
Evidence of menses in the past 12 months Post-menopausal, defined as women who 
have been amenorrheic for at least 12 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 56 of 67 
 
 consecutive months, without other known or 
suspected primary cause.  
Amenorrhea for ≥ 12 months, but the 
amenorrhea is possibly due to other causes, 
including prior chemotherapy, anti -estrogens  
or ovarian suppression Sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy) with surgery at least 4 weeks before  Screen ing. Tubal ligation will 
not be considered a surgically sterile method. 
Subjects who report that they have become pregnant during the study or have a positive pregnancy test at Visit 2, 3 or 4 will be permanently discontinued from the study utilizing protocol -required 
procedures for study discontinuation (Visit 4 pr ocedures). The Principal Investigator  or designee 
must immediately notify the Medical Monitor, sponsor
 LPPV  and sponsor  rep resentative within 24 
hours of learning of the event. The pregnancy will be reported as an AE and all pregnancy reporting criteria wi ll be followed as outlined in section  10.7.6, including the initial use of the  
 (Novartis form) and all required follow -up for the mother and child as outlined 
on the form. For more detailed information refer to the  
. All follow- up information regarding the course of the pregnancy, 
including perinatal and neonatal outcome will be communicated to the Medical Monitor, sponsor 
 and sponsor representatives as per the sponsor requirements. 
12.3.10  Report
ing Safety Information to the IRB  
The Investigator  must promptly report to the Investigator ’s IRB all unanticipated problems 
involving risks to subjects. This includes death from any cause and all SAEs  occurring during t he 
study, regardless of the assessed causality.20 
12.3.11  Record Retention  
The study will be conducted according to GCP  as outlined in International Conference on 
Harmonisation ( ICH) step 5 guidelines by the FDA. It is the responsibility of the Investigator  to 
maintain a comprehensive and centralized filing system of all relevant documentation.  
Investigator s will be instructed to retain all study records required by the sponsor, as well as the 
regulations, in a secure and safe facility, off of the ground, with limited access.  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 57 of 67 
 
 All study- related  documentation must be retained. This includes, but is not limited to: 
• Study Contract 
• Study Protocol and all Amendment with Investigator  Signature Pages 
• Source Data 
• eCRFs  and Data Queries 
• Regulatory Documents 
• IRB Documentation (i.e., approvals, correspondence, follow ups, close out) 
• IP Receipt and Return Records  
• Retention Selection and all IP Accountability Records 
• ICFs 
• All Logs and Forms 
• Monitoring Reports and Letters 
• Correspondence 
Regulations require t he Investigator  must retain  all records  according to 21 CFR 312.62(c) for a 
period of 2 years following the date the marketing application is approved for the IP for the 
indication for which it is being investigated; or, if  no application is to be filed or if the application 
is not approved for such indication, until 2 years after the investigation is discontinued and FDA is 
notified. However, Fougera requires the  Investigator  retain  all records  for a period of  after 
termination of the s tudy unless CRO or sponsor  authorizes, in writing, earlier destruction.  No 
documents shall be transferred from the site (i.e. , to an off -site storage facility) without first 
notifying the sponsor. No documents shall be destroyed without the sponsor's written approval. If the Investigator  can no longer support the retention of the records (i.e., due to retirement or death), 
the documents must be transferred to a new responsible party. The sponsor must be notified of this transfer in wri ting. 
12.3.12  Study Monitoring and Auditing  
Monitoring and Auditing by the CRO  
 will be responsible for monitoring the study according to GCP  and applicable regulations. 
Monitoring visits are for the purpose of training, confirming adherence to the protocol and to verify 
complete and accurate data collection. A monitoring plan will be agreed upon between the sponsor 
and the CRO. The Investigator  will be visited by a monitor before  the study, at regular intervals 
during the course of the study and at the completion of the study. Investigator  audits will also be 
conducted, the details of which would be described in a separate audit plan . Site Monitoring visits 
and audits (as applicable) will be scheduled with the Investigato r in advance of the visit at a 
mutually agreed time.  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 58 of 67 
 
 The study monitor will review the ICFs  and verify eCRF entries by comparing them with the source 
documents. The monitor will review the maintenance of regulatory documentation and IP 
accountability. The monitor will review the progress of the study  on a regular basis with the 
Investigator  and other site personnel. The clinical site will make all records associated with the 
study available to  representative during such monitoring visits and audits. It is the 
Investigator ’s responsibility to:  
• Provide the monitor with sufficient time to review the eCRFs and relevant source 
documents 
• Be available to answer questions and/or resolve data clarifications and/or implement 
corrective and preventative actions (as required following a site audit) 
• Provide adequate time and space for these visits  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 59 of 67 
 
 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 60 of 67 
 
  
 
Aud
it by the Sponsor and/or Regulatory Authorities  
The s
tudy may be subject to audit by the sponsor, sponsor r epresentative, the IRB  or by regulatory 
authorities. The sponsor will schedule any audits in advance of the visit. Regulatory authority audits 
may take place at any time during or after the study without advance notice. If such an audit occurs , 
the Investigator  must agree to allow access to requi red subject  records. By signing this protocol, 
the Investigator  grants permission to personnel from the sponsor, its representatives and appropriate 
regulatory authorities for on- site monitoring of all appropriate study documentation, as well as on-
site review of study procedures. 
12.3.13  Confidentiality, Use of Information and Publication  
All information supplied by the sponsor in connection with this study and not previously published, 
is considered confidential information. This information includes, but is not limited to, data, 
materials (i.e. , the clinical protocol, e CRFs ), equipment, experience (whether of a scientific, 
technical, engineering, operational, or commercial nature), designs, specifications, know -how, 
product uses, processes, formulae, costs, financial data, marketing plans and direct selling systems, 
customer lists and technical and commercial information relating to customers or business projections used by the sponsor in its business. Any data, inventions  or discoveries collected or 
develope d, as a result of this study is considered confidential. This confidential information shall 
remain the sole property of the sponsor, shall not be disclosed to any unauthorized person or use in any unauthorized manner without written consent of the sponsor, and shall not be used except in the performance of the study.  
The information developed during the course of this clinical study is also considered confidential, 
and will be used by the sponsor in connection with the development of the drug. The informat ion 
may be disclosed as deemed necessary by the sponsor. To allow the use of the information derived 
from this clinical study, the Investigator  is obliged to provide the sponsor with complete test results 
and all data developed in the study. The informatio n obtained during this study may be made 
available to other Investigators who are conducting similar studies.  
The Investigator  shall not make any publication related to this study without the express written 
permission of the sponsor. Should the Investigat or wish to publish or present the results of this 
study, the Investigator  agrees to provide the sponsor with an abstract, manuscript, and/or 
presentation for review ninety (90) days before  submission for publication/presentation. The 
sponsor retains the ri ght to delete from the manuscript confidential information and to object to 
suggested publication and/or its timing (at the sponsor’s sole discretion.) 
12.3.14  End of the Trial  
Upon a subject's completion in the study, the IP will no longer be available to the subject and all 
used and unused IP must be collected. T he Investigator  can, at their discretion, discuss alternative 
treatments with the subject . 

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 61 of 67 
 
 The end of the trial is defined as the time at which the last subject  has completed their last visit in 
the study . All eCRFs will be completed in compliance with the protocol and all relevant data and/or 
records will be forwarded to the CRO, as applicable. The Investigator  must submit a final report to 
the IRB. The monitor will conduct a close out visit at the site. 
12.3.15  Clinical Study  Report  
At the end of the study a full report per requirements of sponsor and regulatory authorities will be 
prepared which will include a narrative of the clinical conduct and results of the study, a statistical 
report including a descriptio n of the analysis performed, and other documentation as may be 
appropriate. The report will be in electronic format according to eCTD and ICH formatting standards and guidelines.
21 ANDA summary tables will also be generated. Data sets will be 
provided in SAS® transport (.xpt) format with appropriate description (Read Me) files as required 
by FDA. 
12.3.16  Termination  of the Study  
The s ponsor reserves the right  to terminate the study at any time for administrative or safety 
reasons.  If the sponsor prematurely terminates or suspends the study, or one or more investigative 
sites participating in the study, the Investigator and/or CRO (as contracted) must promptly inform 
the IRB. As applicable, the Investigator may be required to follow  up on the subject and/or refer 
them for appropriate care.  
  
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 62 of 67 
 
  
  

CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 63 of 67 
 
 14.0 APPENDICES  
14.1 APPENDIX A: Investigator’s Global Assessment  of Disease Severity  
 
Score  Grade  Definition   
0 None No plaque elevation above normal skin level ; may have residual non -
erythematous discoloration ; no psoriatic scale ; no erythema  
1 Minimal  Essentially flat with possible trace elevation; faint  erythema; no psoriatic scale  
2 Mild  Slight but definite elevation of plaque above normal skin level; may have up to 
moderate erythema (red coloration); fine scales with some lesions partially 
covered  
3 Moderate Moderate elevation with rounded or sloped edges to plaque; moderate erythema 
(red coloration); somewhat coarse scales with most lesions partially covered  
4 Severe  Marked elevation with hard, sharp edges to plaque; severe erythema (very red 
coloration); coarse, thick scales with virtually all lesions covered and a rough 
surface  
5 Very 
Severe  Very marked elevation with very hard, sharp edges to plaque; very severe 
erythema (extreme red coloration); very coarse, thick scales with all lesions 
covered and a very rough surface  
To be eligible for participation in the study a subject  must  have a Baseline IGA  score of 3, 4 or 5. 
A subject  shall be considered a “ treatment  success” if he/she has an IGA score  of 0, 1 or 2 within the 
treatment area at the Week 12 visit . 
 
  
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 64 of 67 
 
 14.2 APPENDIX B: Psoriasis Area Severity Index at the Target Lesion Site  
 
 
 
Score   
 
Grade   
 
Erythema   
 
Scaling   
 
Plaque Elevation  
0 Clear  No evidence of 
erythema  No evidence of scaling  No evidence of plaques 
above normal skin level  
1 Almost 
Clear  Pink discoloration, 
minimal erythema  Occasional fine scales 
hardly noticeable  Slight, just discernible  
elevation above normal 
skin level  
2 Mild  Light red coloration  Slight but definite 
roughness, fine scale 
present, no cracking  Discernible  elevation above 
normal skin level u pon 
examination, but not 
pronounced  
3 Moderate  Moderate redness, but 
not dark Moderate roughness, 
somewhat coarse 
scaling  Definite plaque formation 
with rounded/sloped edges 
to plaque  
4 Severe  Dark red coloration  Marked roughness, 
coarse/thick scaling, cracking may be 
evident  Marked elevation with 
hard, distinct edges to plaque 
5 Very 
Severe  Very dark red 
coloration with induration present Very thick scales 
covering extensive area, severe cracking/fissures may 
be evident  Very marked elevation, 
very hard  and sharp edges 
to plaque 
To be eligible for participation in the study a subject  must have a minimum plaque elevation of at least 
moderate severity (score ≥ 3) at the target lesion site. The most severe lesion at B aseline should be 
identified as the target lesion . 
  
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 65 of 67 
 
 14.3 APPENDIX C: Application Site Reactions  
The following application site reactions will be evaluated at each visit based on the scale provided 
below:  
 
Signs and Symptoms:  
Erythema  
Dryness  
Burning/S tinging  
Erosion Edema  
Pain 
Itching 
Grading Scale:  
Severity  Grade  
Absent 0 
Mild  1 (slight, barely perceptible)  
Moderate 2 (distinct presence) 
Severe  3 (marked, intense) 
 
 
  
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 66 of 67 
 
 14.4 APPENDIX D: TAZORAC® (tazarotene) Product Insert  
 
   
 
    
 
   
 
    
 
    
 
   
 
    
 
   
 
    
 
CONFIDENTIAL PROTOCOL  
A Multi -Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing 
Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a 
Vehicle Control in the Treatment of Stable Plaque Psoriasis  
 
Confidential  0453-01-01  Rev. 2   12/22/2016  Fougera Pharmaceuticals Inc.    Page 67 of 67 
 
 14.5 APPENDIX E: Amendments to the Protocol 
Amendment  Date   
1 12/20/2016   
The following revisions were made to the protocol dated 07/26/2016.  
• Updated approximate number of sites to be used.  
• Section 10.4.5 Black backing on label removed  
• Section 10.7.1 Updated reference in Adverse drug reaction section.  
• Section 10.7.6 Pregnancy reporting start date clarified; Removed language regarding males impregnating females
. 
 
Amendment  Date   
2 12/22/2016   
• Section 11.6 Updated Cochran -Mantel -Haenszel  exact test in Superiority to Placebo Analysis  
 